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Abstract 
Chronic kidney disease has become a worldwide public health problem as it is linked with an 
increase in the incidence and prevalence rate of patients with renal failure who require renal 
replacement therapy with high healthcare costs and poor outcomes. Moreover, chronic 
kidney disease (CKD) in its earlier stages is associated with a higher prevalence of many 
adverse outcomes such renal failure, cardiovascular disease, and premature death. In Saudi 
Arabia, the total number of patients who are receiving renal replacement therapy has been 
increasing rapidly in recent decades, as the Saudi Centre for Organ Transplantation data has 
demonstrated, while the estimated annual cost for treating end-stage renal disease uses 
around 3.8% of the total Ministry of Health’s budget in Saudi Arabia. This means that more 
attention is required for the prevention and management of CKD and its risk factors in Saudi 
Arabia. Therefore, this thesis was formulated to review the quality of healthcare management 
for patients with chronic kidney disease in Saudi Arabia. This review was achieved based on: 
(I) assessing and describing the epidemiology of end-stage renal disease, (II) assessing pre 
end-stage renal disease care practice, (III) examining the indications for hospital admission 
among haemodialysis patients. The findings have revealed that the burden of end-stage renal 
disease has increased substantially in Saudi Arabia particularly among middle-aged diabetic 
and hypertensive patients, while the most prevalent co-morbid conditions were hypertension 
and Hepatitis C virus infection. Detecting patients with chronic kidney disease in the earlier 
stages, and pre end-stage renal disease care practices and its outcomes should be improved 
in Saudi Arabia. Furthermore, cardiovascular diseases play a major role in increasing the rate 
of hospitalization and mortality among patients with end-stage renal disease. In conclusion, 
this review stressed the needs and the importance of multidisciplinary preventive strategies 
for leading causes of end stage renal disease (ESRD) and improving pre ESRD nephrology care 
practices and its outcomes in Saudi Arabia. This will not be possible to achieve without 
collaboration between healthcare providers and a comprehensive national health information 
system to allow consistent assessment of the quality of healthcare management and provide 
an updated evidence-based health policy that will help healthcare providers to choose the 
best intervention that will help to improve healthcare practice outcomes and allocate 
healthcare resources. 
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CHAPTER 1 
Introduction 
Overview of the healthcare system in Saudi Arabia 
Demographic and economic patterns of Saudi Arabia 
Demographic patterns 
The Kingdom of Saudi Arabia has the largest and fastest growing population among the 
countries of the Gulf Cooperation Council (1). The recent figures from the population census 
that was carried out by the Central Department of Statistics and Information (CDSI) in Saudi 
Arabia in 2012 estimated the population of Saudi Arabia at 29.2 million, with the annual 
Saudi population growth rate being around 2.9%, with a high density of population in the 
main cities, particularly Riyadh and Jeddah. Saudi citizens comprise around 68% of the total 
population, and around 57% of the total population are males (2). A high percentage of the 
Saudi population are less than 24 years (47.8%) old, while the age group of 25-64 years 
represents 49.1% of the population. Elderly people who are more than 65 years old 
represent only 3.1% of the population (1). Estimates based on the census project that the 
population will reach 37.6 million by 2025 (2) as a result of the high birth rate of 22.5 per 
1,000, contrasted with the mortality rate of 3.8 per 1,000 and increased life expectancy of 
around 72.6 years for men and 76.7 years for females (1). The high percentage of young 
people and foreign workers in the country will affect the future shape and direction of the 
Saudi healthcare system (3). Furthermore, the growth of the population address the rapidly 
increasing demand for essential healthcare services and facilities, and creates more 
opportunities for healthcare investments (4). 
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Economic patterns 
Saudi Arabia plays a leading role in the Organisation of the Petroleum Exporting Countries 
(OPEC) and is ranked as the largest producer and exporter of petroleum in the world. 
Therefore the petroleum sector accounts for around 80% of budget revenues (5, 6). Although 
the economy of Saudi Arabia is based on oil, in recent decades it has diversified. Currently, 
Saudi Arabia produces and exports a variety of industrial goods rather than petroleum all over 
the world (6). The growth in the Saudi economy has had a significant impact on increasing the 
Saudi community income in recent decades for the per capita Gross Domestic Product (GPD) 
related to the United States Dollar (US$) 18,080 in 2003 to US$ 25,700 in 2012 (2, 7). The 
Human Development Report 2013 reveals that Saudi Arabia is ranked at a high level (57th in 
the world) in the Human Development Index (0.78).(8). This improvement in income has had 
a significant impact in many sectors in the country, including the health sector. 
The structure of healthcare services 
The Saudi healthcare system consists of: (1) the governmental sector, which provides 
healthcare services free of charge and includes the Ministry of Health (MOH) and other 
governmental agencies; and (2) the private sector, which requires out-of-pocket health 
expenditure and plays a key role in providing quality healthcare services [Figure 1.1]. The 
Ministry of Health (MOH) in Saudi Arabia is the main provider and funder of healthcare 
services. It provides 60% of the healthcare services in Saudi Arabia and operates 244 public 
hospitals with 33,277 beds, along with 2037 primary healthcare centres. Each centre provides 
healthcare services to an average of 12456 individuals (9). Furthermore, it provides full and 
free access to all public healthcare services to all citizens and expatriates working within the 
public sector (10). The other governmental agencies include referral hospitals such as the King 
Faisal Specialist Hospital & Research Centre, security forces medical services, army forces 
medical services, National Guard health affairs, Ministry of Higher Education hospitals, 
ARAMCO hospitals, the Royal Commission for Jubail & Yanbua health services, the school 
health units of the Ministry of Education and the Red Crescent Society. All these agencies 
provide all levels of healthcare services to a defined population, who are employees in these 
agencies and their dependants, except for referral hospitals, the Red Crescent Society and the 
teaching hospitals. The other governmental hospitals operate 39 hospitals including 10822 
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beds. The private sector also plays a role in delivering healthcare services particularly in large 
cities with 125 hospitals including 11833 beds and 2218 dispensaries and clinics (9). 
The advancement in healthcare services in Saudi Arabia, as well as other factors, should 
contribute to improving population health by increasing the institutions of health education 
and training, with regard to improved life conditions and increased health awareness among 
the community. However, there is no coordination or any clear communication channels 
between multidisciplinary healthcare providers such as guidelines of referral from primary to 
secondary care and health information systems network. This leads to waste of healthcare 
resources and duplicates the effort of providing healthcare services for the population (4). 
The Ministry of Health 
Healthcare services in Saudi Arabia have improved remarkably in recent decades in terms of 
quantity and quality, as they have been given a high priority by Saudi government (3, 11, 12). 
The MOH, which is also known as the public healthcare system, plays the major role in 
managing, planning and creating health polices, and supervising health programmes. Also, it 
monitors healthcare services and advises other governmental agencies and the private sector 
to achieve the government’s health targets (13, 14). The MOH supervises 20 regional 
directorates general of health affairs all over the country (15), and provides three levels of 
healthcare services: primary, secondary, and tertiary care (9). Primary healthcare centres 
provide preventive and curative services, and refer patients that require advanced care to 
public hospitals, which represent secondary care, while patients who need more complex 
levels of care are transferred to central or specialised hospitals, which represent tertiary 
healthcare (4). 
However, the MOH has run the centralised management of health services by playing 
multiple roles including financing, operating, controlling, supervising, and managing the public 
health sector (4). This current model of healthcare management may not be able to achieve 
public health targets in the future unless well-planned strategies are undertaken to separate 
these multiple roles (3, 4, 16). Various feasible strategies were suggested including 
decentralising management of health services by giving more authority to the regional 
directorates in terms of planning, recruitment of healthcare professionals, formulating 
agreements with operating companies, giving some limited financial discretion and 
16 
encouraging the privatisation of public hospitals (3, 4). This could help to reduce the annual 
government expenditure on healthcare services besides producing new financial revenues for 
the MOH and improving healthcare services and applying the cooperative health insurance 
scheme (4, 13, 16).  
 
Figure 1.1. The structure of healthcare services in Saudi Arabia (4, 9) 
 
Health workforce 
In Saudi Arabia, there is a shortage of national health workers such as physicians, nurses, and 
pharmacists compared to developed countries and other Gulf Cooperation Council (GCC) 
countries [Table 1.1] (17). This shortage of healthcare professionals can influence the quality 
of delivery of healthcare services. Moreover, the majority of the healthcare professionals in 
the country are expatriates, while Saudis comprise around 38% only of the total health 
workforce (9). This leads to a very high rate of turnover and instability in the health workforce 
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(16). Despite the efforts that have been taken by the Saudi government in teaching and 
training Saudis for healthcare professionals careers, the proportion of the Saudi health 
workforce is anticipated to decline in the future as a result of the expansion in healthcare 
facilities around the country (4). 
Table 1.1. Health workforce per 10,000 members of the population in the period between 2005 and 2012 (17) 
Countries Physicians Nurses Pharmacist 
GCC countries 
Bahrain 14.9 38.6 2.5 
Kuwait 17.9 45.5 3 
Oman 20.5 44.9 4.4 
Qatar 27.6 73.7 12.6 
Saudi Arabia 9.4 21 0.6 
United Arab of Emirates 19.3 40.9 5.9 
Other countries 
Germany 36.9 113.8 9.5 
Japan 21.4 41.4 21.5 
United Kingdom 27.7 94.7 6.7 
United States 24.2 98.2 8.8 
 
Healthcare finance and expenditure 
The public health financing comes mainly from government revenues and the healthcare 
services are provided free of charge in public healthcare centres in Saudi Arabia. There has 
been rapid growth in the population and a growing awareness of health issues in the 
community (3), while the costs of healthcare technology have escalated. Government 
expenditure on the MOH has increased continuously from 2.8% of the national budget in 
1970 (15) to 6% in 2005 and 6.9% with expenditure per capita reaching US$375 in 2011 (9, 
18). However, the World Bank data reveals that the percentage of the total health 
expenditure in both public and private sectors as a percentage of the GDP of Saudi Arabia in 
2011 was 3.7%, which is still behind many developed nations in the world such as the United 
States (17.9%), United Kingdom and Japan (9.3%), and China (5.2%) (19). 
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Health insurance in Saudi Arabia 
The Council for Cooperative Health Insurance (CHI) was established in 1999 by the 
government, with its main roles including introducing, regulating, and supervising health 
insurance strategy for the Saudi healthcare market. In order to meet the growing demands of 
the population for healthcare services and to ensure the quality of the healthcare services 
being provided (20), the implementing of CHI scheme is planned to be achieved over three 
stages. The first stage is to apply CHI to Saudis and non-Saudis who work in the private sector, 
so that their employers have to pay for covering the healthcare cost of their dependants. The 
second stage is to apply the CHI to Saudis and non-Saudis who work in the government 
sectors, while the government have to pay the CHI costs for this category of employee. The 
third stage is to apply CHI for other groups such as pilgrims to the holy places in Makkah City 
and Madinah City of Saudi Arabia. To date the first stage has been implemented only, while 
the government is working systematically to implement the second stage of the CHI for 
employees in the government sector and the third stage for pilgrims, before privatising the 
public hospitals. (3, 4) 
Accessibility to healthcare services 
The recent MOH statistics demonstrate that there is an unsatisfactory distribution of 
healthcare services and healthcare professionals across the geographical areas of Saudi 
Arabia (9). Also, many healthcare seekers experience long waiting lists for many healthcare 
services and facilities (3). There is a lack of healthcare services for disadvantaged groups such 
as the elderly and disabled people, particularly in rural areas (4).  Furthermore, many people 
such as those who live in the borders and remote areas are not able to access healthcare 
services (4). However, optimising the accessibility of healthcare services requires equity in 
allocating the resources of healthcare services and facilities based on the density of the 
population across the country beside the cooperation between all healthcare sectors in the 
country (14). 
National health information systems (e-health) 
The need to develop electronic national health information systems has been increasing in 
Saudi Arabia. Health information systems have become one of the most challenging and 
promising fields of research, education, strategic planning and administration to improve the 
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equability, standards, and the efficiency and quality of healthcare services (21-23). In Saudi 
Arabia, electronic health information systems have been started up in a number of non-MOH 
hospitals and organisations such as the King Faisal Specialist hospital and research centre, the 
National Guard health services, the medical services of the armed forces, and university 
hospitals. Developing health information system is processed slowly in MOH institutions. 
Moreover, there are many information systems operating in the regional directorates and in 
central hospitals which are not connected to each other or to private hospitals or other 
agencies (24). In order to reinforce the use of e-health strategies and to build up a 
comprehensive health information system, more coordination is required between different 
healthcare providers. This will help to prevent the duplication and wasting the resources of 
healthcare services, and to provide better healthcare practices. 
Burden of diseases  
The main patterns of disease in Saudi Arabia have changed from communicable to non-
communicable diseases and these require more attention from the MOH (10). There is a 
scarce data in the literature on the increasing prevalence of chronic diseases in Saudi Arabia 
such as diabetes, hypertension, cardiovascular disease, chronic renal disease, genetic blood 
disorders, and obesity (25-28). All these diseases are associated with worse health outcomes, 
complex clinical management, and increased healthcare cost (29). Furthermore, the mortality 
rate in Saudi Arabia due to non-communicable disease was the highest (644 per 100,000) 
compared to other causes of mortality, which includes communicable disease (86 per 
100,000) and injuries (68 per 100,000) in 2008 (17). Reactive strategies for treating chronic 
diseases and their complications are costly, and may even be ineffective in certain conditions. 
For instance, the estimated annual cost of treating diabetes mellitus in Saudi Arabia is 
US$1.87 billion (30) while the estimated annual cost for treating end-stage renal disease 
involves using around 3.8% of the total MOH budget (27). Therefore, a proactive strategy 
should be the most effective way to reduce the prevalence of chronic diseases and their 
complications, and thus the associated healthcare costs will be reduced. 
The strategy for reforming healthcare system  
The MOH has set a strategy to reform the healthcare system and to improve the quality of 
healthcare services in Saudi Arabia, which was approved by the council of ministers in 2009. 
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This strategy will be achieved within 20 years. The objectives of the strategy are focused on 
diversifying funding sources, developing a comprehensive health information system, 
developing the health workforce, activating the role of MOH in supervising and monitoring 
healthcare services, encouraging the private sector to help in providing healthcare services, 
improving the quality of preventive and curative also rehabilitative care, and improving the 
equity of healthcare service distribution across the country. (4) 
Challenges facing healthcare services 
Although a huge effort has been undertaken by the MOH to reform the Saudi healthcare 
system and to improve the quality of healthcare services, many challenges remain. These 
include tackling the shortages in the health workforce, working with limited financing 
resources while the population is growing rapidly, the inequity to accessibility of healthcare 
services across the country, applying the cooperative health insurance scheme to all 
categories of people, the privatisation of public hospitals, the utilisation of national health 
information systems and the changing patterns of communicable and non-communicable 
diseases. (3, 4) 
Renal care in Saudi Arabia 
Chronic diseases may be prevented sometimes by controlling other related diseases or risk 
factors. This can improve the quality of life and reduce the utilisation of healthcare services 
and expenditures. Chronic kidney disease (CKD) is related to many chronic diseases in terms 
of aetiology and consequences (31). Also, it has a significant impact on the quality of life and 
productivity (32), and life expectancy (33). Furthermore, the treatment of such disease is 
costly, particularly if the patient has progressed to the fifth stage of CKD/end-stage kidney 
disease (estimated glomerular filtration rate (eGFR)= <15mL/min/1.73 m2) and requires renal 
replacement therapy (RRT) to survive (34, 35).  
In Saudi Arabia, the total number of patients who are receiving RRT has been increasing 
rapidly in recent decades, as the Saudi Centre for Organ Transplantation (SCOT) data has 
demonstrated [Figure 1.2], with average of annual increase in the dialysis population of 
around 8% [Figure 1.3] (36). Corresponding to this increase, a rapid expansion has occurred in 
dialysis facilities from a solitary centre in 1971 to 182 dialysis centres across the country in 
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2012. A large percentage of these facilities are provided by the MOH, while the non-MOH and 
private sectors also contribute to providing dialysis facilities (36). This means increasing the 
demands of healthcare services with limited health resources, which may affect the quality of 
care. Therefore, attention to both the prevention and management of CKD is required in 
Saudi Arabia.  
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Figure 1.2. The rapid increase of patients who receive renal replacement therapy in Saudi Arabia between 
1995 and 2012 (36) 
 
 
 
Figure 1.3. Current and projected dialysis population for the period 1995-2020 in Saudi Arabia (36) 
 
23 
CHAPTER 2 
Aim and objectives 
The aim of this thesis is to review the quality of healthcare management for patients with 
chronic kidney disease (CKD) in Saudi Arabia, as CKD is associated with worse health 
outcomes, more complex clinical management, and increased healthcare cost.  This review 
was conducted based on three objectives: the first objective is assessing and describing the 
epidemiology of end-stage renal diseases to determine the aetiology and the burden of the 
disease. The second objective is to assess the quality of pre ESRD care and its consequences, 
as undiagnosed or late detection cases of CKD are associated with an increased incidence rate 
and burden of ESRD. The third objective is to examine the indications of hospitalisation 
among haemodialysis patients, which may reflect the severity of patients’ co-morbid 
conditions and the quality of renal care practices, and associated with high healthcare cost. 
Objective (1) 
Conducting a systematic review and Meta-analysis to assess the results of all relevant 
epidemiological studies of end-stage renal disease (ESRD) in Saudi Arabia and other Gulf 
Cooperation Council countries (GCC) up to 2010 to describe the epidemiology of ESRD in 
these countries based on: the incidence and prevalence of ESRD and the mortality rate in the 
ESRD population; the distribution of demographic characteristics, and RRT; the aetiology of 
renal disease; co-morbidity conditions in the ESRD population; and Primary causes of death in 
the ESRD population. These methods were used because a lack of comprehensive national 
health information systems in these countries, data that do exist are unsatisfactory and 
insufficient: most data are either recorded by referring centres rather than community 
hospitals such as Saudi Centre for Organ Transplantation, or based on small studies. However, 
analyses of the epidemiology of ESRD itself in this region are also inconsistent. These 
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conflicting analyses of the epidemiology of ESRD mean that synthesising and assessing the 
available evidence would be valuable to show the epidemiological pattern of ESRD in Saudi 
Arabia and other GCC countries. (See chapter 3) 
Objective (2) 
Conducting a cross-sectional study to assess pre-ESRD care and to investigate the primary 
causes of ESRD in two of the most active MOH hospitals in the western region of Saudi Arabia 
after applying for an ethical approval from the Ministry of Health & General Directorate of 
Health Affairs for data collection. Also, investigating the potential factors that may be 
associated with late referral to nephrology care and examining its consequences. The 
participants were prevalent patients in 2011 due to time limitations for collecting data and a 
lack of national health information systems in Saudi Arabia. A critical data for assessing pre-
ESRD care were missing from the medical records such as laboratory and clinical 
measurements before and at time of initiating dialysis. Therefore, pre-ESRD nephrology care 
was reviewed based on describing multiple indicators including reasons for referral to 
nephrology care, referral source to nephrology care, pre-ESRD care period, and vascular 
access type at the first dialysis. (See chapter 4) 
Objective (3) 
Conducting a retrospective cohort study in one of the most active MOH hospitals in Makkah 
City in Saudi Arabia after applying for an ethical approval from the Ministry of Health & 
General Directorate of Health Affairs for data collection, to examine the indications for 
hospitalisation among haemodialysis patients by investigating the following: the primary 
reasons for hospital admissions; and risk factors that increase the number of hospital 
admissions, and which increase length of stay in hospital. Participants were prevalent 
patients in 2011 due to time limitations for collecting data and a lack of national health 
information systems in Saudi Arabia. Each patient was followed-up retrospectively, from the 
first date of initiating haemodialysis to the end of 2011. This method was used because only 
two studies in the literature have reported the primary reasons for hospitalisation among the 
haemodialysis population in Saudi Arabia. The first study conducted in Riyadh City reported 
cardiovascular disease as the primary reason for hospitalisation (37). The second study 
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conducted in Al-Madinah City reported vascular access related problems as the primary 
reason (38). Neither study investigated the risk factors that might increase the rate of hospital 
admissions or the length of stay in hospital per patient-year on haemodialysis, which could 
reflect both the severity of patients’ co-morbid conditions and the quality of healthcare 
services. (See chapter 5) 
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CHAPTER 3 
Epidemiology of end-stage renal disease in the countries 
of the Gulf Cooperation Council: a systematic review 
Abstract 
Background 
End-stage renal disease (ESRD) has become a public health problem worldwide, with recent 
reports showing that the total number of ESRD patients has been growing dramatically. 
Scarce data are available on the epidemiology of ESRD in the countries of the Gulf 
Cooperation Council (GCC). In the absence of comprehensive national renal registries in these 
countries, the data that are available are inaccurate and unreliable. This review was 
conducted to assess the results of all relevant studies to show the epidemiological pattern of 
ESRD in the countries of the GCC. 
Aims 
To describe the epidemiology of ESRD in the countries of the GCC based on: (1) the trends of 
the incidence and prevalence rate of ESRD, mortality rate in ESRD population, (2) 
demographic distribution and renal replacement therapy, (3) primary causes of ESRD, (4) co-
morbid conditions in ESRD population, (5) causes of mortality in ESRD population. 
Methods 
A systematic review was conducted by searching Medline and EMBASE databases to identify 
all relevant papers published up to 2010. The publication references were reviewed to 
identify any further relevant studies. Two reviewers independently applied the inclusion and 
exclusion criteria, and carried out data extraction, and quality assessment of studies. Finally, 
the data related to the incidence, prevalence, mortality rate of ESRD, and demographic 
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distribution and renal replacement therapy were analysed descriptively, and where possible a 
meta-analysis was performed to summarise the prevalence of all outcomes related to primary 
causes of ESRD, co-morbid conditions, and causes of death. 
Results 
44 studies met the inclusion criteria from the search. This review shows that the incidence of 
ESRD has increased while the prevalence and mortality rate of ESRD in the GCC has not been 
reported sufficiently. The leading primary causes of ESRD recorded in the countries of the 
GCC is diabetes 25.9% (95%CI: 20.7%, 31%) with the most prevalent co-morbid conditions 
being hypertension 66.7% (95%CI: 49.6%, 83.8%) and Hepatitis C Virus infection 41.4% 
(95%CI: 24.5%, 58.2%); the most common causes of death were cardiovascular disease 44.8% 
(95%CI: 25.2%, 64.3%) and sepsis 19.6% (95%CI: 12.6%, 26.6%). 
Conclusion 
This review highlights that the lack of a comprehensive national renal registry data or health 
information system is a critical issue in the countries of the GCC. The available data also do 
not provide an accurate and up to date estimate for relevant outcomes. Additionally, 
considering the increasing burden of chronic kidney disease, these results stress the 
importance of preventative strategies for leading causes of ESRD. Furthermore, additional 
studies are needed to describe the epidemiological pattern of ESRD and for assessing the 
overall quality of renal care to provide an updated evidence-based health policy. 
Background 
End-stage renal disease (ESRD) is defined as irreversible decline in kidney function, when 
renal replacement therapy (RRT) is needed for survival. There are two main types of RRT: 
dialysis and kidney transplantation (39). Kidney transplantation is preferred for patients with 
ESRD, since it offers a longer life span, superior quality of life, and is more cost effective than 
long-term dialysis (40, 41). ESRD has become a public health concern worldwide, with recent 
reports showing that the total number of ESRD patients has been growing dramatically. The 
rising prevalence is due largely to two main factors: the ageing of the population and the 
global epidemic of diabetes (42-45). 
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The countries of the Gulf Cooperation Council (GCC), which consist of Saudi Arabia, the 
United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman, share boundaries and a similar 
background of culture and ethnicity, while their socio-demographic distributions and 
socioeconomic development are also similar [Figure 2.1] (46). Although the countries of the 
GCC have experienced noticeable advances in delivering healthcare, the burden of non-
communicable diseases, which generate higher healthcare cost, is increasing rapidly (4, 47). 
Many reports have shown evidence of increasing prevalence of the most common causes of 
ESRD in the GCC: the prevalence of obesity in these countries, which is associated with multi-
chronic diseases (48), exceeds that in developed countries because of their rapid economic 
growth and associated changes in lifestyle (26, 49, 50). Furthermore, the International 
Diabetes Federation reports that five of the countries of the GCC ranked globally among the 
top ten countries in the world for diabetes prevalence (51, 52). 
The growing incidence of ESRD is increasing the use of RRT, as well as generating greater 
morbidity, which leads to more hospitalisations (53). ESRD also has a significant effect on 
quality of life and life expectancy (54, 55). These, in turn, increase healthcare expenditures, 
placing a heavy financial burden on healthcare funders and general populations to meet the 
growing needs of patients with ESRD (56-59). 
ESRD has a significant effect on public health in the countries of the GCC, as the policy of these 
countries provides free healthcare services in government hospitals, including RRT to the 
populations based on clinical need without any restrictions in terms of age, gender, or social 
status. The majority of RRT facilities are provided by the government sector; therefore, any 
increase in its use would be associated with a significant increase of healthcare expenditures. 
Scarce data are available on the epidemiology of ESRD in the countries of the GCC. In the 
absence of health information systems or a comprehensive national renal registry data 
system in these countries, data that do exist are unsatisfactory and insufficient: most data are 
either recorded by referring centres rather than community hospitals such as Saudi Centre for 
Organ Transplantation (SCOT) data (60), or based on small studies. However, analyses of the 
epidemiology of ESRD itself in this region are also inconsistent. For example, the prevalence 
of ESRD decreased between 1986 and 2005, which was a period when risk factors for the 
disease became more common; this might be due to underreporting the cases of ESRD (61, 
62), or might be influenced by mortality and renal transplant rate. Other studies report 
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inconsistent results of primary causes of ESRD (57, 63). These conflicting analyses of the 
epidemiology of ESRD mean that synthesising and assessing the available evidence would be 
valuable to show the epidemiological pattern of ESRD in the countries of the GCC. 
?
Figure 3.1. The countries of the Gulf Cooperation Council map (64) 
 
Aims and scope 
This review was conducted to assess the results of all relevant epidemiological studies of 
ESRD in the countries of the GCC up to 2010 to describe the epidemiology of ESRD in these 
countries based on: 
?? The incidence, prevalence rate of ESRD, and mortality rate in ESRD population 
?? The distribution of demographic characteristics, and RRT 
?? The aetiology of renal disease 
?? Co-morbid conditions in the ESRD population 
?? Primary causes of death in the ESRD population. 
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Methods 
Systematic review 
Searching 
A systematic review was conducted by searching the Ovid database, which included Medline 
and EMBASE databases, to identify all relevant papers published between 1950 and 2010 
without any restrictions on the language of publications, using the following keywords in the 
searching strategy: End stage, terminal, chronic, renal, kidney, Arab, Middle East, Arabian 
Gulf, Saudi Arabia, Kuwait, and United Arab Emirates, Oman, Qatar, and Bahrain [Appendix 
A]. Additionally, the reference lists of all identified papers were reviewed to locate other 
studies, which were not identified in the database search. 
Selection criteria 
Inclusion criteria 
Study design and principal outcomes 
Any observational epidemiological study, including cohort studies, case-control studies, cross-
sectional studies, and ecological studies, reporting ESRD incidence, prevalence, primary 
causes, co-morbid conditions, and mortality rate /causes were included in this review. 
Defining population and setting 
All of the studies that have been included defined the study population to have ESRD or 
patients on regular dialysis for a minimum dialysis period of at least three months in any of 
the countries of the GCC. Since many outcomes were reviewed in this systematic review, 
studies that estimated the incidence and prevalence of ESRD as outcomes should not have 
defined the study population as ESRD population or patients on regular dialysis. 
Exclusion criteria 
Studies where the study population mainly comprised children, or pregnant woman, or 
patients on dialysis without mentioning the dialysis period or a period less than three months 
were excluded, to avoid including patients with acute kidney disease. In addition, studies that 
used qualitative methods or epidemiological studies that did not report any statistical 
information about any relevant outcomes were excluded. 
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Data abstraction and validity assessment 
All potential relevant publications, which were obtained from searching databases, their titles 
and abstracts were reviewed independently by two reviewers to identify relevant papers. 
Then, the full texts of the papers were reviewed to identify epidemiological studies that 
fulfilled the selection criteria above. Studies that met the inclusion criteria for the review had 
data extracted. Data relating to study design, setting, definition of outcome measures, 
inclusion and exclusion criteria of the study population, methodological quality using the 
Newcastle Ottawa Scale (NOS) (65) and outcomes were then independently extracted by two 
reviewers using standardised data extraction form [Appendix B]. In the methodological 
quality assessment NOS, the included studies were classified after aggregating the score as 
follows:  scores of six or higher were chosen to indicate higher methodological quality, a score 
less than six indicates a lower methodological quality. 
Data analyses 
The extracted data for patients’ characteristics, prevalence, incidence, and mortality rate of 
ESRD were analysed descriptively. 
Quantitative data synthesis 
The outcomes, primary causes, co-morbid conditions, and causes of mortality were classified 
for analyses. Primary causes of ESRD were classified as in the ICD9-CM code (66) into the 
following categories: diabetes, glomerulonephritis (GN), secondary GN/vasculitis, interstitial 
nephritis/pyelonephritis, hypertension/large vessel disease, cystic/hereditary/congenital 
diseases, neoplasms/tumours, and miscellaneous conditions. Co-morbid conditions were 
classified into three groups: chronic diseases including diabetes, hypertension, cardiovascular 
disease; infectious diseases including hepatitis C virus (HCV), hepatitis B virus (HBV), 
tuberculosis (TB), catheter-related infection, and peritonitis; and other co-morbid conditions 
included anaemia, bone disease, gastrointestinal abnormalities, liver disease, depression, 
malnutrition, and restless leg syndrome. Mortality causes were classified into cardiovascular 
disease, cerebrovascular disease, sepsis, malfunction of dialysis access, pulmonary disease, 
including pulmonary infection and pulmonary embolism, hepatic failure, gastrointestinal 
bleeding, and malignancy. 
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The data related to primary causes, co-morbid conditions, and causes of death were entered 
into STATA version 11 for statistical analysis. These data then were used to conduct meta-
analysis to summarise the estimate of the prevalence for each outcome where possible. The 
degree of heterogeneity was assessed between the studies statistically using meta-analysis to 
obtain an I-square value (67). This review combined the results from observational studies; 
therefore, it would be expected that the value of I-square would be high due to sampling and 
methodological and statistical variation of the studies. To account for the anticipated 
heterogeneity, the DerSimonian and Laird model random effect method was used to combine 
the effect size (68, 69). Subgroup analysis was performed when it was necessary and possible 
to investigate the reasons for heterogeneity between the studies; it was used to assess the 
differences between locations and time. Furthermore, the measures of uncertainty (95% 
confidence intervals (95%CIs)) were calculated where meta-analysis was not appropriate to 
conduct for any outcome, especially for those that were reported in less than three studies. 
Results 
The search identified 226 articles published from 1950 up to 2010. After reviewing the titles and 
abstracts, 70 were obtained for full text review and 156 excluded. Twenty-two studies were 
excluded after reviewing the full text and two studies were included after reviewing the reference 
lists of each paper. Fifty studies were eligible for data extraction; six studies were excluded due to 
the nature of the study population or because they failed to report any outcome measures of 
interest. Mitwalli (1991) (70) and Al-Shohaib (1999) (71) were excluded because, although the 
study population was defined as dialysis patients, no further background was provided such as 
the dialysis period, so the study may have included patients with acute renal failure. Al-Mohaya 
(1990) (72), Yahya (1998) (73), Rafi (2007) (74) and Al-Jahdali (2009) (75) were excluded because 
no relevant statistical outcomes were reported [Table 2.1]. After the search inclusions and 
exclusions, 44 epidemiological studies were eligible for the systematic review [Figure 2.2]. 
Characteristics of included studies 
There were 40 studies conducted in Saudi Arabia in different regions. One study was 
conducted in the United Arab Emirates/Abu-Dhabi (76), one was conducted in Kuwait (77), 
one was conducted in Bahrain (78), and another one included the entire GCC (79). There were 
no studies from either Oman or Qatar meeting the inclusion criteria. The majority of studies 
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were either cross-sectional studies (19) or cohort studies (19), and there were 6 case-control 
studies. Only 11 studies of the 44 included were given a high score in methodological quality 
assessment according to NOS because most of the included studies were not reported 
adequately. Although the other 33 included studies were given a low score, they were 
included in this review to avoid bias [Table 2.2]. 
 
 
Figure 3.2. A flaw chart shows a summary of the systematic review 
 
N= 226 potentially relevant references were 
identified from searching electronic database 
n= 22 references excluded 
after reviewing the full texts 
because they were not 
observational studies 
n= 6 studies excluded mostly 
because the study 
population or failed to report 
at least one outcome 
measure 
n= 156 references excluded 
on the basis of title and 
abstract 
n= 2 studies were identified 
from searching reference 
lists 
n =44 studies were included in the systematic 
review 
n= 70 full copies retrieved 
and assessed for eligibility 
Nine (9) studies reported incidence rate, three (3) studies reported prevalence rate, eight 
(8) studies reported mortality rate, twenty-one (21) studies reported primary causes of 
ESRD, thirty-one (31) studies reported co-morbid conditions in patients with ESRD, and 
six (6) studies reported causes of mortality in ESRD. 
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Table 3.1. Summary of excluded studies 
Ref Author Year Title Study design Location Quality Sample size Age range Male % RRT 
(72) Al-Mohaya 1990 
Arteriovenous fistula for haemodialysis a 
report of 112 consecutive cases 
Cross-
sectional 
KSA/East-Al-
Khobar 
2 112 13-75 59.8 HD/RT 
(70) Mitwalli 1991 
Tuberculosis in patients on maintenance 
dialysis 
Cross-
sectional 
KSA/Centre-
Riyadh 
3 25 34-40 26 _ 
(73) Yahya 1998 
Analysis of 490 kidney biopsies data from 
the United Arab emirates renal disease 
registry 
Cross-
sectional 
UAE/ 
Abu Dhabi 
3 490 14-66 NR _ 
(71) Al-Shohaib 1999 
Tuberculosis in active dialysis patients in 
Jeddah 
Cross-
sectional 
KSA/West-
Jeddah 
2 210 NR NR _ 
(74) Rafi 2007 
Monitoring iron status in end-stage renal 
disease patients on haemodialysis 
Cross-
sectional 
KSA/East-
Dammam 
1 24 29-65 79 _ 
(75) Al-Jahdali 2009 
Advanced care planning preferences 
among dialysis patients and factors 
influencing their decisions 
Cross-
sectional 
KSA/Centre-
Riyadh 
2 100 36-66 53 _ 
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Table 3.2. Summary of included studies 
Ref Author Year Title 
Study 
design Location Quality 
Sample 
Size 
Mean of 
age Age range Male % 
RRT 
HD% PD% RT% 
(80) Hussein 1990 
Tuberculosis in patients undergoing 
maintenance dialysis 
Cohort 
KSA/ 
West-Taief 
4 205 42 20-60 26 62.4 13.17 _ 
(81) Hussein 1990 
Chronic intermittent peritoneal dialysis 
using automatic cycler machine 
Cross-
sectional 
KSA/ 
West-Taief 
1 28 NR 6 -74 42 _ 100 _ 
(82) Fakunle 1991 
Prevalence of antibodies to hepatitis C 
virus in haemodialysis patients in 
Riyadh 
Cross-
sectional 
KSA/ 
Centre-
Riyadh 
3 190 40.4 15 -75 63.2 100 _ _ 
(61) Ibrahim 1992 
End-stage renal disease (ESRD) in Saudi 
Arabia 
Cross-
sectional 
KSA 2 822 NR NR 50.7 98 2 _ 
(76) Shakuntala 1992 
End-stage renal disease in native 
population of the United Arab Emirates 
Cohort 
UAE/ 
Abu Dhabi 
4 96 45 11 - 75 NR 52.1 _ 47.9 
(83) Al-Nasser 1992 
Seropositivity to hepatitis C virus in 
Saudi haemodialysis patient 
Case 
control 
KSA/ 
South-Baha 
5 66 46 30-68 53.81 100 _ _ 
(84) Mitwalli 1992 
Hepatitis C in chronic renal failure 
patients 
Case-
control 
KSA/ 
Centre-
Riyadh 
2 30 NR NR NR 86.6 13.3 _ 
(77) El-Reshaid 1994 
End-stage renal disease and renal 
replacement therapy in Kuwait-
epidemiological profile over the past 4 
1/2 years 
Cohort Kuwait 7 647 NR NR 63.7 75.1 21.2 3.7 
(85) Hussein 1994 
Observations in Saudi Arabian dialysis 
population over a 13-year period 
Cross-
sectional 
KSA/ 
West-Taief 
4 325 43 6-89 53.84 63.8 1.2 35 
(86) Mitwalli 1995 
The incidence of End-stage renal 
disease in two regions of the Kingdom 
of Saudi Arabia 
Cohort 
KSA/ 
Gaizan, 
Madinah 
7 
Madinah= 
108, 
Gaizan= 
187, 
Total=295 
NR 11-75 61 _ _ _ 
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Ref Author Year Title Study 
design 
Location Quality Sample 
Size 
Mean of 
age 
Age range Male % RRT 
(87) Huraib 1995 
High prevalence of and risk factors for 
hepatitis C in haemodialysis patients in 
Saudi Arabia: a need for a new dialysis 
strategies 
Cross-
sectional 
KSA 4 1147 43.4 28-58 50.56 100 _ _ 
(88) Soyannwo 1996 
Hepatitis C antibodies in haemodialysis 
and pattern of end-stage renal failure 
in Gassim-Saudi Arabia 
Cross-
sectional 
KSA/ 
Centre-
Gassim 
4 96 NR 11-80 51.04 100 _ _ 
(89) Mitwalli 1997 
Aetiology of end-stage renal disease in 
two regions of Saudi Arabia 
Cross-
sectional 
KSA/ 
Gaizan, 
Madinah 
4 
Madinah=
45, 
Gizan=82,
Total=127 
Madinah=
50, 
Gaizan=37 
37 -50 61.41 _ _ _ 
(90) Al-Homrany 1997 
Successful therapy of tuberculosis in 
haemodialysis patients 
Cross-
sectional 
KSA/ 
South-
Abha 
3 270 51.2 25-70 23 100 _ _ 
(91) Kumar 1997 
Hepatitis C virus infection among 
haemodialysis patients in the Najran 
region of Saudi Arabia 
Cross-
sectional 
KSA/ 
South-
Najran 
3 47 44.1 16- 85 55.31 100 _ _ 
(92) Al-Ghamdi 1998 
Whole blood total, reduced and 
oxidised ascorbic acid levels in Saudi 
patients with chronic renal failure: 
influence of gender and chronic 
haemodialysis 
Case-
control 
KSA/ 
Centre-
Riyadh 
4 55 33 23-43 50.98 100 _ _ 
(93) Al-Homrany 1998 
Incidence of treated end-stage renal 
disease in Asir region, southern Saudi 
Arabia 
Cohort 
KSA/ 
South-Asir 
8 114 47.89 9 - 99 56.1 _ _ _ 
(94) Mitwalli 1998 
Spectrum of renal osteodystrophy in 
dialysis patients at a tertiary hospital- 
Riyadh- Saudi Arabia 
Cross-
sectional 
KSA/ 
Centre-
Riyadh 
4 57 42 14 -78 50.9 80.7 19.3 _ 
(95) Al-Muhanna 1999 
Disease profile complications and 
outcome in patient on maintenance 
haemodialysis at King Faisal University 
Hospital_ Saudi Arabia 
Cohort 
KSA/East-
Khobar 
6 233 45.5 34-57 65.6 100 _ _ 
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Ref Author Year Title Study 
design 
Location Quality Sample 
Size 
Mean of 
age 
Age range Male % RRT 
(96) 
Suberamani
an 
2001 
Haemodialysis utilisation in a single 
centre dialysis unit_ in the Kingdom of 
Saudi Arabia 
Cohort 
KSA/ 
South-
Gizan 
4 393 40.7 10 - 93 46.6 86.5 _ 13.5 
(97) Youmbissi 2001 
CAPD in Dammam Central Hospital_ 
Saudi Arabia: a Five year experience 
Cohort 
KSA/East-
Dammam 
3 31 41.3 10 - 85 32.25 _ 100 _ 
(98) Al-Homrany 2001 
Psycho-social features of chronic 
dialysis patients in Saudi Arabia: 
experience of one centre 
Cross-
sectional 
KSA/ 
South-
Abha 
3 54 NR NR 50 100 _ _ 
(37) Al-Wakeel 2002 
Morbidity and mortality in ESRD 
patients on dialysis 
Cohort 
KSA/ 
Centre-
Riyadh 
4 110 53.8 17 - 92 64.5 59.1 29.1 11.8 
(99) Shaheen 2002 
Pre-End stage chronic renal failure: the 
Jeddah kidney centre experience 
Cohort 
KSA/ 
West-
Jeddah 
6 99 49.5 11 - 90 58.6 _ _ _ 
(100
) 
Khan 2002 
A study of end stage renal disease 
patients from southern part of Arabian 
peninsula 
Cross-
sectional 
KSA/ 
South-
Najran 
4 67 39 13 - 66 55.22 100 _ _ 
(78) Al-Haddad 2003 
Depression among end stage renal 
disease patients 
Case 
control 
Bahrain 4 45 52 NR 46.7 100 _ _ 
(101
) 
Saxena 2003 
The susceptibility of patients with type-
2 diabetes to hepatitis C virus infection 
during long-term haemodialysis 
Cohort 
KSA/East-
Hafouf 
7 196 52.8 14 - 84 50.51 100 _ _ 
(102
) 
Saxena 2003 
The prevalence of Nasal carriage of 
Staphylococcus aureus and associated 
vascular access-related septicaemia 
among patients on haemodialysis in Al-
Hasa region of Saudi Arabia 
Cohort 
KSA/East-
Hafouf 
3 208 47.5 15 - 84 45.7 100 _ _ 
(103
) 
Al-Khunaizi 2003 
End stage renal disease experience in a 
general hospital in eastern Saudi 
Arabia 
Cohort 
KSA/East-
Dhahran 
4 37 60 NR 50 97.8 2.2 _ 
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Ref Author Year Title Study 
design 
Location Quality Sample 
Size 
Mean of 
age 
Age range Male % RRT 
(104
) 
Al-Mueilo 2004 
Gastro-duodenal lesions and 
Helicobacter pylori infection in 
haemodialysis patients 
Case 
control 
KSA/East-
Khobar 
3 54 NR 16-85 59 100 _ _ 
(105
) 
Mohamed 2004 
Incidence and aetiology of end-stage 
renal disease in Madinah Munawarah 
Area: Any changing trends? 
Cohort 
KSA/West-
Madinah 
5 106 NR >13 61.6 _ _ _ 
(106
) 
Saxena 2004 
The impact of nurse understaffing on 
the transmission of hepatitis C virus in 
a hospital-based haemodialysis unit 
Cohort 
KSA/East-
Hafouf 
7 198 47 15-84 54 100 _ _ 
(107
) 
Saxena 2004 
The vulnerability of middle-aged and 
elderly patients to hepatitis C virus 
infection in a high-prevalence hospital 
based haemodialysis 
Cohort 
KSA/East-
Hafouf 
6 198 47 15-84 54 100 _ _ 
(108
) 
Saxena 2004 
Advancing age and the risk of nasal 
carriage of Staphylococcus aureus 
among patients on long-term hospital-
based haemodialysis 
Cohort 
KSA/East-
Hafouf 
6 205 NR 15-84 46.8 100 _ _ 
(109
) 
Gabr 2004 
Cardiac tropinin T and end stage renal 
disease 
Cross-
sectional 
KSA/ 
Centre-
Buraidah 
3 73 NR 27-78 45.2 100 _ _ 
(110
) 
Mohamed 2005 
Morbidity and mortality in ESRD 
patients on  regular haemodialysis: a 
single centre experience 
Cohort 
KSA/ 
West-
Madinah 
4 395 51 13-85 58.5 100 _ _ 
(111
) 
Abdelrahma
n 
2006 
Tuberculosis in end-stage renal disease 
patients on haemodialysis 
Cross-
sectional 
KSA/East-
Dammam 
3 256 38 21-75 39 100 _ _ 
(79) Al-Suwaida 2007 
The Gulf survey on anaemia 
management GSAM 2005 
Cross-
sectional 
GCC 4 563 53.9 >18 52 100 _ _ 
(112
) 
Al-Khunaizi 2007 
Patterns of renal pathology among 
renal biopsy specimens in eastern 
Saudi Arabia 
Cohort 
KSA/East-
Dhahran 
6 95 41 23-59 55 _ _ _ 
(113
) 
Al-Shatwi 2007 
Nutritional assessment of 
haemodialysis patients 
Cross-
sectional 
KSA/ 
Centre-
Riyadh 
4 61 52 35-69 47.5 100 _ _ 
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Ref Author Year Title Study 
design 
Location Quality Sample 
Size 
Mean of 
age 
Age range Male % RRT 
(114
) 
Al-Ali 2008 
Increased prevalence of glycoprotein 
IIb/IIIa Leu33Pro polymorphism in end 
stage renal disease patients on 
haemodialysis 
Case-
control 
KSA/East-
Dammam 
7 42 50 38-65 68 100 _ _ 
(115
) 
Al-Wakeel 2009 
Micro-vascular and Marco-vascular 
complications in diabetic nephropathy 
patients referred to nephrology clinic 
Cross-
sectional 
KSA/ 
Centre-
Riyadh 
3 184 61.9 19-85 69.6 _ _ _ 
(116
) 
Al-Jahdali 2009 
Restless legs syndrome in patients on 
dialysis 
Cross-
sectional 
KSA/ 
Riyadh- 
Jeddah 
4 114 55.7 39-73 53.7 76.3 23.7 _ 
(117
) 
Al-Saran 2009 
Nutritional assessment of  patients in a 
large Saudi dialysis unit 
Cross-
sectional 
KSA/ 
Centre-
Riyadh 
4 200 50 18-82 54 100 _ _ 
 
RRT= renal replacement therapy, HD=haemodialysis, PD= peritoneal dialysis, RT=renal transplantation, ESRD=end-stage renal disease, NR= not reported 
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Epidemiology of ESRD in the GCC countries 
Patient’s characteristics 
Demographic distribution 
The arithmetic mean of the mean age of participants with ESRD in included studies in the 
review is 47 years old (standard deviation (SD) = ±6.4); some studies included children (aged 
<18 years old) but in a very small proportion compared to adults, while three studies reported 
neither the age range of the study population nor the mean age. In the United Arab Emirates, 
the highest incidence rate of ESRD was reported in Abu-Dhabi city among the 45-55 years age 
group (76) while the median age among ESRD patients was 45 years in Kuwait (77). In Saudi 
Arabia, many studies conducted in the 1990s showed that the incidence and prevalence of 
ESRD were linked directly to increasing age (70, 87). One study conducted in the Asir province 
showed that the incidence of ESRD is directly proportional to increasing age as follows: the 
incidence rate of the patients who aged between 15-44 years is 199.8 per million population 
(pmp), 45-64 years is 577.7 pmp, and >65 years is 716 pmp (93). The arithmetic mean of the 
proportions of males for all included studies in the review is 52.3 (SD= ±9.9), which is slightly 
higher than the proportion of females 47.4 (SD= ± 9.8). Only two included studies did not 
report the proportion of male to female study participants [Table 2.2]. 
Renal replacement therapy 
The study population was defined as haemodialysis patients in 24 included studies, and other 
studies reported the proportion of haemodialysis patients ranged between 52.1% and 97.8%. 
In two studies, the study population was defined as peritoneal dialysis, while other studies 
reported that the proportion of peritoneal dialysis ranged between 1.2% and 29.1%. Only five 
studies reported the proportion of renal transplant ranging between 3.7% and 47.9%. 
Haemodialysis treatment was clearly the dominant RRT followed by renal transplantations 
and peritoneal dialysis [Table 2.2]. 
The incidence rate of ESRD 
One study conducted in a general hospital in the United Arab Emirates in Abu-Dhabi city 
reported the annual incidence rate of ESRD at 73.6 pmp in 1992 (76); another population-
based study conducted in Kuwait reported the annual incidence rate of ESRD as 72 pmp in 
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1994 (77). Six studies were conducted in Saudi Arabia in different regions between 1995 and 
2007. It was difficult to track the trend of the incidence rate between these studies, but some 
of them show that the incidence rate seems to be increasing. For example, two studies 
conducted in Saudi Arabia in Al-Madinah City demonstrate that the incidence rate had 
increased from 65.2 pmp in 1995 to 137.5 pmp in 2004 (86, 105), while in another region of 
Saudi Arabia, in Gizan, the mean annual growth rate was reported to be 7.44% in the period 
from 1987 to 2000 (96) [Table 2.3]. 
The prevalence rate of ESRD 
The prevalence rate of ESRD was reported in three studies. Two studies were based on 
national data: one was conducted in Kuwait and reported the prevalence of ESRD as 80.6 pmp 
in 1994 (77); the other was conducted in Saudi Arabia and reported the prevalence of ESRD as 
139 pmp in 1986. This latter estimation was based on 29 centres around the Kingdom; by 
geographical region, the highest prevalence was found in the central region followed by the 
eastern region of Saudi Arabia (61). The most recent study was a single centre study 
estimating the prevalence of ESRD as 38% among diabetic patients in Riyadh City in Saudi 
Arabia (115) [Table 2.4]. 
Mortality rate among ESRD patients 
Mortality rate was not reported sufficiently either. Most included studies reported the 
cumulative death events ranging from 5.3% to 22.6%, which was not useful in terms of 
tracking the trends in mortality rates. However, it might reflect the variety of quality of 
healthcare services between healthcare centres. Three studies were conducted in Saudi 
Arabia in different regions reporting the annual mortality rate as follows: 9.3% in Gizan, and 
8% in Riyadh and Dharan. These show that mortality rates did not change significantly in the 
period between 2001 and 2003 (96, 103, 118). Also, the reported mortality rate in those 
studies might be underestimated as some deaths outside hospitals might not had been 
reported [Table 2.5]. 
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Table 3.3. Summary of reported incidence rate  
Ref Author Year Location 
ESRD 
patients Sample 
Incidence 
rate 
Time 
intervals 
(76) Shakuntala 1992 UAE/Abudhabi 96 NR 73.6 pmp 14 year 
(77) El-Reshaid 1994 Kuwait 647 NR 72 pmp 4.5 year 
(86) Mitwalli 1995 KSA/South-Gizan 124 654685 189.4 pmp 7 month 
(93) Al-Homrany 1998 KSA/South-Asir 114 NR 214.9 pmp 6 year 
(96) Subermanian 2001 KSA/South-Gizan NR 172446 *7.44% 13 year 
(103) Al-Khunaizi 2003 KSA/East-Dhahran 37 250000 148 pmp 4 year 
(112) Al-Khunaizi 2007 KSA/East-Dhahran 12 95 **13% 7 year 
(86) Mitwalli 1995 KSA/West-Madinah 54 828477 65.2 pmp 7 month 
(105) Mohamed 2004 KSA/West-Madinah 106 NR 137.5 pmp 1 year 
 
* The mean annual growth rate, 
** This estimation was based on a single study per 100 population, NR=not reported 
 
Table 3.4. Summary of reported prevalence  
Ref Author Year Location ESRD patients Sample Prevalence rate 
(61) Ibrahim 1992 KSA 822 5913669 138 pmp 
(77) El-Reshaid 1994 Kuwait NR NR 80.6 pmp 
(115) Al-Wakeel 2009 KSA/Centre-Riyadh 70 184 *38% 
 
*Prevalence of ESRD among diabetic patients, NR=not reported 
 
Table 3.5. Summary of reported mortality rate 
Ref Author Year Location Death 
ESRD 
patients 
Mortality 
rate 
Time 
intervals 
(119) Al-Wakeel 2002 KSA/Centre-Riyadh 29 110 *8.07% 5 year 
(95) Al-Muhanna 1999 KSA/East-Khobar 53 233 22.60% 13 year 
(103) Al-Khunaizi 2003 KSA/East-Dhahran NR 37 *8% 4 year 
(112) Al-Khunaizi 2007 KSA/East-Dhahran 5 95 5.30% 7 year 
(96) Subermanian 2001 KSA/South-Gizan NR 393 *9.3% 13 year 
(110) Mohamed 2005 KSA/West-Madinah 12 94 12.80% 6 month 
(85) Hussein 1994 KSA/West-Taief 46 325 14% 13 year 
(77) El-Reshaid 1994 Kuwait 95 647 14.70% 4.5 year 
 
* Annual death rate, NR=not reported 
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Primary causes of ESRD 
Diabetic nephropathy 
Meta-analysis results showed that the summarised estimate of diabetic nephropathy (DN) 
prevalence as a cause of ESRD in the countries of the GCC was 25.87% (95%CI: 20.69%, 
31.05%) and the heterogeneity between the studies was high (I-square= 91.5%). Subgroup 
analysis by period of time shows that the summarised estimate of DN prevalence had 
significantly increased from 16.93% (95%CI: 13.01%, 20.84%; I-square= 68.9%) in the period 
1990-1999 to 32.91 (95%CI: 27.70%, 38.13%; I-square= 80.2%) in the period 2000-2010 
[Figure 2.3]. Subgroup analysis by location shows that the summarised estimate of DN 
prevalence appears to be higher in urban or more developed areas than rural areas. For 
instance, in Saudi Arabia the summarised estimate of DN prevalence is 32.20%  (95%CI: 
23.99%, 40.40%; I-square= 63.5%) in the western region, 30.97% (95%CI: 23.99%, 37.95%; I-
square= 73.95%) in the eastern region, and 25.09% (95%CI, 15.78%, 34.40%; I-square= 83.3%) 
in the central region compared to 13.72% (95%CI: 4.29%, 23.15%; I-square=67.4%) in the 
southern region, which is considered a less developed area [Figure 2.4] [Table 2.6]. 
Hypertensive nephropathy 
The hypertension and large vessel disease group included renal vascular disease and 
nephrosclerosis, which occurred as a result of severe blood pressure. The summarised 
estimate of hypertensive nephropathy prevalence in the countries of the GCC is 13.52% 
(95%CI: 9.36%, 19.01%) and the heterogeneity between the studies was high (I-square= 
91.9%). Subgroup analysis by period of time showed that the prevalence of hypertensive 
nephropathy has not changed in the last two decades, while the summarised estimate of 
hypertensive nephropathy prevalence is 12.94% (95%CI: 6.45%, 19.44%; I-square= 93.3%) in 
the period 1990-1999 and 14.18% (95%CI: 9.36%, 19.01%; I-square= 83.2%) in the period 
2000-2010 [Figure 2.5]. Subgroup analysis by location shows that the highest estimate of 
hypertensive nephropathy prevalence was found in Saudi Arabia in the central region 23.60% 
(95%CI: 12.80%, 34.40%; I-square= 89.1%), followed by western region 12.67% (95%CI: 5.35%, 
19.98%; I-square= 79.3%), eastern region 12.55% (95%CI: 3.61%, 21.49%; I-square= 56%) and 
southern region 4.45% (95%CI: 1.57%, 7.34%; I-square= zero%) [Figure 2.6] [Table 2.7]. 
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Glomerulonephritis 
The summarised estimate of glomerulonephritis prevalence as a cause of ESRD in the 
countries of the GCC is 18.77% (95%CI: 14.19%, 23.35%) and the heterogeneity between the 
studies was high (I-square= 92.6%). Subgroup analysis by period of time showed that the 
summarised estimate of GN prevalence had declined from 24.53% (95%CI: 15.93%, 33.13%; I-
square= 93.3%) in the period 1990-1999 to 13.95% (95%CI: 9.56%, 18.34%; I-square= 87.4%) 
in the period 2000-2010 [Figure 2.7]. Subgroup analysis by location in Saudi Arabia 
demonstrated that the highest estimate of GN prevalence found in eastern region 27.68% 
(95%CI: 16%, 39.36%; I-square= 92.7%), followed by the central region 15.74% (95%CI: 7.93%, 
23.55%; I-square= 85.6%), southern region 14.16% (95%CI: -0.28%, 28.59%; I-square= 94.2%) 
and western region 8.02% (95%CI: 5.38%, 10.67%; I-square= 0%) [Figure 2.8] [Table 2.8]. 
Secondary glomerulonephritis/Vasculitis 
This group includes haemolytic uremic syndrome (HUS) and Systemic Lupus Erythematosus 
(SLE) nephritis. The prevalence of HUS as a primary cause of ESRD was reported as just 1.3% 
(95%CI: 0.27%, 3.72%) by one study conducted in Saudi Arabia in the eastern region. The 
summarised estimate of SLE prevalence is 4.39% (95%CI: 2.78%, 6%) and the heterogeneity 
between the studies was high (I-square=65.6%) [Figure 2.9] [Table 2.9]. 
Interstitial Nephritis/Pyelonephritis 
This group included interstitial nephritis, pyelonephritis, obstructive uropathy, and analgesic 
abuse. The summarised estimate of interstitial nephritis prevalence is 4.09% (95%CI: 1.52%, 
6.67%) with high heterogeneity (I-square= 80.1%) [Figure 2.10]. Pyelonephritis prevalence is 
10.72% (95%CI: 4.82%, 16.62%) with high heterogeneity (I-square= 96.3%) [Figure 2.11]; and 
obstructive uropathy prevalence is 4.93% (95%CI: 3.51%, 6.35%) with moderate 
heterogeneity (I-square= 59.3%) [Figure 2.12]. Analgesic abuse prevalence was reported in 
two studies: one study reported the prevalence at 1.7% (95%CI: -0.04%, 9.4%) (94) and 
another study reported the prevalence at  2% (95%CI: 0.56%, 5.1%) (101) [Table 2.10]. 
Cystic/Hereditary/Congenital diseases 
This group includes polycystic kidney disease, medullary cystic disease, and 
congenital/hereditary diseases. The summarised estimate of polycystic kidney disease 
prevalence is 3.56% (95%CI: 2.77%, 4.36%) with an I-square of 0% [Figure 2.13], medullary 
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cystic disease prevalence is 1.53% (95%CI: 0.56%, 2.50%) with an I-square of 0% [Figure 2.14], 
while the summarised estimate of hereditary and congenital disease prevalence is 5.03% 
(95%CI: 2.28%, 7.77%) with high heterogeneity (I-square=87.3%) [Figure 2.15] [Table 2.11]. 
Miscellaneous 
This group of conditions included ESRD of uncertain aetiology (unknown), and other 
conditions that are rarely reported as causes of ESRD, such as schistosomiasis, TB, sickle cell 
nephropathy, and contrast nephropathy. For these conditions, for which the aetiology is 
uncertain, the summarised estimate is 20.96% (95%CI: 14.89%, 27.04%) with high 
heterogeneity (I-square= 94.9%), and subgroup analysis by period of time showed that 
reporting the aetiology of renal disease has not improved in the last two decades as the 
summarised estimate of reporting the cause of ESRD as uncertain aetiology did not change 
significantly from the period 1990-1999 to the period 2000-2010 [Figure 2.16]. The 
summarised estimate for conditions that are rarely reported is 2.37% (95%CI: 1.07%, 3.68%) 
with an I-square of 73.8% [Figure 2.17] [Table 2.12]. 
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Figure 3.3. Forest plot showing the pooled estimate and subgroup analyses by time of the prevalence of 
diabetic nephropathy as a cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.4. Forest plot showing the pooled estimate and subgroup analyses by locations of the prevalence of 
diabetic nephropathy as a cause of ESRD in Saudi Arabia. 
NOTE: Weights are from random effects analysis
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Figure 3.5. Forest plot showing the pooled estimate and subgroup analyses by time of the prevalence of 
hypertensive nephropathy as a cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.6. Forest plot showing the pooled estimate and subgroup analyses by location of the prevalence of 
hypertensive nephropathy as a cause of ESRD in Saudi Arabia. 
NOTE: Weights are from random effects analysis
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Figure 3.7. Forest plot showing the pooled estimate and subgroup analyses by time of the prevalence of 
glomerulonephritis as a cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.8. Forest plot showing the pooled estimate and subgroup analyses by location of the prevalence of 
glomerulonephritis as a cause of ESRD in Saudi Arabia. 
NOTE: Weights are from random effects analysis
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Figure 3.9. Forest plot showing the pooled estimate and subgroup analyses by time of the prevalence of 
Systemic Lupus Erythematosus as a cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.10. Forest plot showing the pooled estimate and subgroup analyses by time of the prevalence of 
interstitial nephritis as a cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.11. Forest plot showing the pooled estimate of the prevalence of pyelonephritis as a cause of ESRD in 
the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.12. Forest plot showing the pooled estimate the prevalence of obstructive uropathy as a cause of ESRD 
in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.13. Forest plot showing the pooled estimate of the prevalence of polycystic kidney as a cause of ESRD 
in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.14. Forest plot showing the pooled estimate of the prevalence of medullary cystic disease as a cause of 
ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.15. Forest plot showing the pooled estimate of the prevalence of congenital/hereditary diseases as a 
cause of ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.16. Forest plot showing the pooled estimate of the prevalence of uncertain aetiology as a cause of 
ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
.
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Figure 3.17. Forest plot showing the pooled estimate of the prevalence of other conditions as a cause of ESRD in 
the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Table 3.6. Summary of reported diabetic nephropathy as a cause of ESRD 
Ref Author Year Location Sample size 
DN 
No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 13 13.5 
(77) El-Reshaid 1994 Kuwait 647 95 14.7 
(89) Mitwalli 1997 KSA/Gizan, Madinah 127 17 13.4 
(79) Al-Suwaida 2007 GCC  563 223 39.6 
(88) Soyannwo 1996 KSA/Centre 96 19 19.8 
(94) Mitwalli 1998 KSA/Centre 57 11 19.3 
(92) AlGhamdi 1998 KSA/Centre 55 11 20.0 
(119) Al-Wakeel 2002 KSA/Centre 110 26 23.6 
(117) Al-Saran 2009 KSA/Centre 200 82 41.0 
(95) Al-Muhanna 1999 KSA/East 233 65 27.9 
(103) Al-Khunaizi 2003 KSA/East 37 22 59.5 
(101) Saxena 2003 KSA/East 196 54 27.6 
(107) Saxena 2004 KSA/East 198 56 28.3 
(104) Al-Mueilo 2004 KSA/East 54 13 24.1 
(89) Mitwalli 1997 KSA/South 82 3 3.7 
(93) Al-Homrany 1998 KSA/South 114 11 9.6 
(120) Khan 2002 KSA/South 67 13 19.4 
(80) Hussein 1990 KSA/West 28 5 17.9 
(89) Mitwalli 1997 KSA/West 45 14 31.1 
(99) Shaheen 2002 KSA/West 99 29 29.3 
(105) Mohamed 2004 KSA/West 106 39 36.8 
(110) Mohamed 2005 KSA/West 125 50 40 
 
DN= diabetic nephropathy 
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Table 3.7. Summary of reported hypertensive nephropathy as a cause of ESRD 
Ref Author Year Location Sample size 
(HT & LV) 
No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 9 9.4 
(77) El-Reshaid 1994 Kuwait 647 14 2.2 
(89) Mitwalli 1997 KSA/Gizan, Madinah 127 7 5.5 
(79) Al-Suwaida 2007 GCC 563 43 7.6 
(88) Soyannwo 1996 KSA/Centre 96 47 49 
(94) Mitwalli 1998 KSA/Centre 57 6 10.5 
(92) AlGhamdi 1998 KSA/Centre 55 11 20 
(119) Al-Wakeel 2002 KSA/Centre 110 22 20 
(117) Al-Saran 2009 KSA/Centre 200 40 20 
(97) Youmbissi 2001 KSA/East 31 8 25.8 
(103) Al-Khunaizi 2003 KSA/East 37 4 10.8 
(104) Al-Mueilo 2004 KSA/East 54 4 7.4 
(89) Mitwalli 1997 KSA/South 82 3 3.7 
(93) Al-Homrany 1998 KSA/South 114 6 5.3 
(80) Hussein 1990 KSA/West 28 3 10.7 
(89) Mitwalli 1997 KSA/West 45 4 8.9 
(99) Shaheen 2002 KSA/West 99 22 22.2 
(105) Mohamed 2004 KSA/West 106 5 4.7 
(110) Mohamed 2005 KSA/West 94 17 18.1 
 
HT & LV= Hypertension and large vessel disease 
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Table 3.8. Summary of reported Summary of reported glomerulonephritis as a cause of ESRD 
Ref Author Year Location Sample size 
GN 
No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 33 34.4 
(77) El-Reshaid 1994 Kuwait 647 155 24.0 
(89) Mitwalli 1997 KSA/Gaizan, Madinah 127 10 7.9 
(79) Al-Suwaida 2007 GCC 563 96 17.1 
(88) Soyannwo 1996 KSA/Centre 96 8 8.3 
(94) Mitwalli 1998 KSA/Centre 57 18 31.6 
(92) Al-Ghamdi 1998 KSA/Centre 55 14 25.5 
(119) Al-Wakeel 2002 KSA/Centre 110 17 15.5 
(117) Al-Saran 2009 KSA/Centre 200 12 6.0 
(95) Al-Muhanna 1999 KSA/East 233 100 42.9 
(97) Youmbissi 2001 KSA/East 31 14 45.2 
(103) Al-Khunaizi 2003 KSA/East 37 3 8.1 
(101) Saxena 2003 KSA/East 196 45 23 
(107) Saxena 2004 KSA/East 198 30 15.2 
(104) Al-Mueilo 2004 KSA/East 54 20 37 
(89) Mitwalli 1997 KSA/South 82 5 6.1 
(93) Al-Homrany 1998 KSA/South 114 38 33.3 
(120) Khan 2002 KSA/South 67 3 4.5 
(80) Hussein 1990 KSA/West 28 4 14.3 
(89) Mitwalli 1997 KSA/West 45 5 11.1 
(99) Shaheen 2002 KSA/West 99 9 9.1 
(105) Mohamed 2004 KSA/West 106 8 7.5 
(110) Mohamed 2005 KSA/West 125 8 6.4 
 
GN= glomerulonephritis 
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Table 3.9. Summary of reported Summary of reported secondary GN/Vasculitis as causes of ESRD 
Ref Author Year Location Sample size 
HUS SLE 
No. % No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 _ _ 1 1 
(77) El-Reshaid 1994 Kuwait 647 _ _ 18 2.8 
(88) Soyannwo 1996 KSA/Centre 96 _ _ 2 2.1 
(119) Al-Wakeel 2002 KSA/Centre 110 _ _ 11 10 
(117) Al-Saran 2009 KSA/Centre 200 _ _ 6 3 
(95) Al-Muhanna 1999 KSA/East 233 3 1.3 10 4.3 
(101) Saxena 2003 KSA/East 196 _ _ 18 9.2 
(107) Saxena 2004 KSA/East 198 _ _ 18 9.1 
(104) Al-Mueilo 2004 KSA/East 54 _ _ 3 5.6 
(120) Khan 2002 KSA/South 67 _ _ 3 4.5 
(80) Hussein 1990 KSA/West 28 _ _ 1 3.6 
 
HUS= Haemolytic uremic syndrome, SLE= systemic lupus erythematosus 
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Table 3.10. Summary of reported interstitial nephritis/Pyelonephritis as causes of ESRD 
Ref Author Year Location 
Sample 
size 
IN PN OUP AN 
No. % No. % No. % No. % 
(76) Shakuntala 1992 
UAE/Abu 
Dhabi 
96 _ _ 18 18.8 _ _ _ _ 
(77) El-Reshaid 1994 Kuwait 647 _ _ 250 38.6 33 5.1 _ _ 
(89) Mitwalli 1997 
KSA/Gizan, 
Madinah 
127 4 3.1 5 3.9 8 6.3 _ _ 
(79) Al-Suwaida 2007 GCC 563 32 5.7 _ _ _ _ _ _ 
(88) Soyannwo 1996 KSA/Centre 96 _ _ 5 5.2 12 12.5 _ _ 
(94) Mitwalli 1998 KSA/Centre 57 _ _ 8 14 1 1.8 1 1.8 
(92) AlGhamdi 1998 KSA/Centre 55 _ _ 10 18.2 6 10.9 _ _ 
(119) Al-Wakeel 2002 KSA/Centre 110 _ _ 12 10.9 _ _ _ _ 
(117) Al-Saran 2009 KSA/Centre 200 2 1 _ _ 4 2 _ _ 
(95) Al-Muhanna 1999 KSA/East 233 13 5.6 _ _ 15 6.4 _ _ 
(97) Youmbissi 2001 KSA/East 31 _ _ _ _ 4 12.9 _ _ 
(101) Saxena 2003 KSA/East 196 _ _ 18 9.2 3 1.5 4 2 
(107) Saxena 2004 KSA/East 198 _ _ 21 10.6 13 6.6 _ _ 
(104) Al-Mueilo 2004 KSA/East 54 4 7.4 _ _ _ _ _ _ 
(89) Mitwalli 1997 KSA/South 82 2 2.4 5 6.1 6 7.3 _ _ 
(93) Al-Homrany 1998 KSA/South 114 _ _ 1 0.9 3 2.6 _ _ 
(120) Khan 2002 KSA/South 67 _ _ 7 10.4 3 4.5 _ _ 
(80) Hussein 1990 KSA/West 28 _ _ 1 3.6 _ _ _ _ 
(89) Mitwalli 1997 KSA/West 45 2 4.4 _ _ 2 4.4 _ _ 
(99) Shaheen 2002 KSA/West 99 _ _ 4 4 7 7.1 _ _ 
(105) Mohamed 2004 KSA/West 106 _ _ 4 3.8 7 6.6 _ _ 
 
IN= Interstitial nephritis or Tubulo-interstitial nephritis, PN= Pyelonephritis, OUP= Obstructive uropathy, AN= 
Analgesic abuse 
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Table 3.11. Summary of reported Cystic/Hereditary/Congenital diseases as causes of ESRD 
Ref Study ID Year Location 
Sample 
size 
Polycystic 
kidney 
Medullary 
cystic 
Congenital/Her
editary 
No. % No. % No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 6 6.3 1 1 1 1 
(77) El-Reshaid 1994 Kuwait 647 19 2.9 _ _ _ _ 
(89) Mitwalli 1997 
KSA/Gizan, 
Madinah 
127 _ _ _ _ 5 3.9 
(79) Al-Suwaida 2007 GCC 563 17 3 _ _ 4 0.7 
(88) Soyannwo 1996 KSA/Centre 96 _ _ _ _ 23 24 
(94) Mitwalli 1998 KSA/Centre 57 2 3.5 _ _ _ _ 
(117) Al-Saran 2009 KSA/Centre 200 _ _ _ _ 8 4 
(95) Al-Muhanna 1999 KSA/East 233 _ _ _ _ 20 8.6 
(101) Saxena 2003 KSA/East 196 10 5.1 3 1.5 _ _ 
(107) Saxena 2004 KSA/East 198 10 5.1 3 1.5 _ _ 
(104) Al-Mueilo 2004 KSA/East 54 _ 3.7 _ _ 2 3.7 
(89) Mitwalli 1997 KSA/South 82 _ _ _ _ 5 6.1 
(120) Khan 2002 KSA/South 67 4 6 _ _ 4 6 
(80) Hussein 1990 KSA/West 28 _ _ 2 7.1 _ _ 
(89) Mitwalli 1997 KSA/West 45 _ _ _ _ 4 8.9 
(99) Shaheen 2002 KSA/West 99 6 6.1 2 2 _ _ 
(105) Mohamed 2004 KSA/West 106 4 3.8 _ _ _ _ 
 
Medullary cystic disease= renal calculi or nephrolithiasis, Hereditary disease including Alport's syndrome, 
Congenital disease= hypoplastic kidney renal hypoplasia or dysplasia 
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Table 3.12. Summary of reported miscellaneous conditions as causes of ESRD 
Ref Study ID Year Location Sample size 
Aetiology 
uncertain 
*Other 
conditions 
No. % No. % 
(76) Shakuntala 1992 UAE/Abu Dhabi 96 13 13.5 _ _ 
(77) El-Reshaid 1994 Kuwait 647 34 5.3 29 4.5 
(89) Mitwalli 1997 KSA/Gizan, Madinah 127 71 55.9 _ _ 
(88) Al-Suwaida 2007 GCC 563 144 25.6 4 0.7 
(88) Soyannwo 1996 KSA/Centre 96 10 10.4 6 6.3 
(94) Mitwalli 1998 KSA/Centre 57 8 14 1 1.8 
(92) AlGhamdi 1998 KSA/Centre 55 4 7.3 2 3.6 
(119) Al-Wakeel 2002 KSA/Centre 110 22 20 _ 0 
(117) Al-Saran 2009 KSA/Centre 200 44 22 2 1.0 
(95) Al-Muhanna 1999 KSA/East 233 _ _ 3 1.3 
(97) Youmbissi 2001 KSA/East 31 5 16.1 _ _ 
(101) Saxena 2003 KSA/East 196 33 16.8 8 4.1 
(107) Saxena 2004 KSA/East 198 29 14.6 _ _ 
(104) Al-Mueilo 2004 KSA/East 54 4 7.4 _ _ 
(93) Al-Homrany 1998 KSA/South 124 47 37.9 _ _ 
(89) Mitwalli 1997 KSA/South 82 57 69.5 _ _ 
(80) Hussein 1990 KSA/West 28 12 42.9 _ _ 
(89) Mitwalli 1997 KSA/West 45 14 31.1 _ _ 
(99) Shaheen 2002 KSA/West 99 20 20.2 _ _ 
(105) Mohamed 2004 KSA/West 106 39 36.8 _ _ 
 
*Other conditions including rarely reported conditions such as schistosomiasis, tuberculosis, sickle cell nephropathy, 
contrast nephropathy, multiple myeloma and others. 
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Co-morbid conditions 
Chronic diseases 
This group included diabetes, hypertension, defined as an elevation of blood pressure 
(>160/95 mmHg), cardiovascular disease and vascular disease. Meta-analysis showed that 
the summarised estimate of diabetes prevalence is 51.26% (95%CI: 44.81%, 57.72%) with an 
I-square of 69.3% [Figure 2.18]. Hypertension prevalence is 66.67% (95%CI: 49.58%, 83.76%) 
with high heterogeneity (I-square= 97.4%) [Figure 2.19]. The summarised estimate of 
cardiovascular disease prevalence is 28.27% (95%CI: 13.71%, 42.83%) with (I-square= 97.2%) 
[Figure 2.20]. One study reported the prevalence of vascular disease as a co-morbid 
condition to be 11.7% (95%CI: 9.18%, 14.67%) (79) [Table 2.13]. 
Infectious disease 
This group included HCV, HBV, TB, peritonitis, and nasal carriage of Staphylococcus aureus. 
The most frequently reported and prevalent infectious disease in ESRD patients was HCV, 
which is more prevalent among haemodialysis patients than peritoneal dialysis patients. The 
summarised estimate of HCV prevalence is 41.37% (95%CI: 24.54%, 58.21%) with (I-square= 
98.4%). The prevalence of HCV has apparently declined from 44.23% (95%CI: 22.12%, 
66.33%; I-square= 98.9%) in the period 1990-1999 to 34.87% (95%CI: 18.57%, 51.17%; I-
square= 87.2%) in the period 2000-2010 [Figure 2.21]. Three studies were conducted in 
Saudi Arabia in the period 1990-1999 which reported the prevalence of HBV among ESRD 
patients, and the summarised estimate was 32.35% (95%CI: 4.33%, 60.38%; I-square= 
98.5%) [Figure 2.22]. Five studies reported the prevalence of TB among ESRD patients and 
were conducted in Saudi Arabia; the summarised prevalence of TB was 14.56% (95%CI: 6.27, 
22.85; I-square= 96.3%) [Figure 2.23]. The prevalence of nasal carriage of Staphylococcus 
aureus, which is associated with vascular access related septicaemia, was reported as a co-
morbid condition among HD patients in only two studies conducted in Saudi Arabia, in Al-
Hafouf City; both reported the prevalence of nasal carriage of Staphylococcus aureus as 38% 
(95%CI: 31.4%, 45%) (102, 108). The incidence of peritonitis was reported in only one study 
as 0.62% among continuous ambulatory peritoneal dialysis patients, with a prevalence of 
4.69% (95%CI: 2.8%, 7.3%) (97) [Table 2.14]. 
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Other co-morbid conditions and complications 
This group included anaemia, bone disease, gastrointestinal abnormalities, liver disease, 
depression, malnutrition, and restless leg syndrome. Meta-analysis showed that the 
summarised estimate of liver disease prevalence is 17.96% (95%CI: 8.20%, 27.73%) with an 
I-square of 93.9% [Figure 2.24]. The prevalence of anaemia, which is defined as 
haemoglobin <110 g/L or haematocrit<30%, was reported in two studies in this review. One 
study was conducted in Saudi Arabia in Riyadh City, and reported the prevalence of anaemia 
as 47.5% (95%CI: 34.59%, 60.73%) (113), while another study reported the prevalence of 
anaemia for all of the GCC countries to be 33.75% (95%CI: 29.85%, 37.82%) (79). Bone 
disease, which includes osteosclerosis, osteodystrophy, osteopenia, subperiostal erosions, 
bone deformities, soft tissue calcification, and osteomalacia, was reported in only two 
studies, both of which were conducted in Saudi Arabia and reported the prevalence to be 
28.92% (95%CI: 24.05%, 34.18%) in Taief (85) and 70.17% (95%CI: 56.60%, 81.57%) in Riyadh 
(94). The prevalence of depression was reported in two studies: one study conducted in 
Saudi Arabia in Abha City reported the prevalence of depression at 59.26% (95%CI: 45.03%, 
72.43%) (98), while the other study, conducted in Bahrain, reported the prevalence of 
depression among men with ESRD as 48%, which is higher than the level reported among 
women 42% (78). The prevalence of malnutrition was assessed using the subjective global 
assessment score developed to assess post-operative nutritional state, restless leg, and 
gastrointestinal abnormalities; these values were reported as 32% (95%CI: 25.60%, 38.95%) 
(117), 50% (95%CI: 40.49%, 59.51%) (116), and 90.74% (95%CI: 79.70%, 96.92%) (104), 
respectively [Table 2.15]. 
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Figure 3.18. Forest plot showing the pooled estimate of the prevalence of diabetes as a co-morbid condition 
among patients with ESRD in the countries of the GCC. 
 
 
Figure 3.19. Forest plot showing the pooled estimate of the prevalence of hypertension as a co-morbid 
condition among patients with ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.20. Forest plot showing the pooled estimate of the prevalence of cardiovascular diseases as a co-
morbid condition among patients with ESRD in the countries of the GCC. 
 
 
Figure 3.21. Forest plot showing the pooled estimate of the prevalence of HCV as a co-morbid condition 
among patients with ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.22. Forest plot showing the pooled estimate of the prevalence of HBV as a co-morbid condition 
among patients with ESRD in the countries of the GCC. 
 
 
Figure 3.23. Forest plot showing the pooled estimate of the prevalence of TB as a co-morbid condition among 
patients with ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.24. Forest plot showing the pooled estimate of the prevalence of liver disease as a co-morbid 
condition among patients with ESRD in the countries of the GCC. 
 
Table 3.13. Summary of reported chronic disease as co-morbidities in the ESRD population 
Ref Author Year Locations 
Sample 
size 
CVD 
Vascular 
disease 
Hypertension Diabetes 
No. % No. % No. % No. % 
(78) Al-Haddad 2003 Bahrain 45 6 13.3 _ _ 10 22.2 24 53.3 
(79) 
Al-
Suwaida 
2007 GCC 563 166 29.5 66 11.7 480 85.3 238 42.3 
(116) Al-Jahdali 2009 
KSA/Riyadh, 
Jeddah 
227 _ _ _ _ _ _ 118 52 
(85) Hussein 1994 KSA/West 325 19 5.8 _ _ 197 60.6 _ _ 
(119) Al-Wakeel 2002 KSA/Centre 110 36 32.7 _ _ 95 86.4 65 59.1 
(109) Gabr 2004 KSA/Centre 73 42 57.5 _ _ _ _ 39 53.4 
(114) Al-Ali 2008 KSA/East 42 14 33.3 _ _ 32 76.2 22 52.4 
 
CVD= Cardiovascular diseases 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 93.9%, p = 0.000)
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Table 3.14. Summary of reported infectious diseases as co-morbid conditions 
Ref Author Year Location 
Sample 
size 
TB Peritonitis NCOSA HCV HBV 
No. % No. % No. % No. % No. % 
(87) Huraib 1995 KSA 1147 _ _ _ _ _ _ 780 68 _ _ 
(82) Fakunle 1991 
KSA/ 
Centre 
190 _ _ _ _ _ _ 102 53.7 _ _ 
(84) Mitwalli 1992 
KSA/ 
Centre 
30 _ _ _ _ _ _ 8 26.7 _ _ 
(88) Soyannwo 1996 
KSA/ 
Centre 
96 _ _ _ _ _ _ 48 50 8 8.3 
(97) Youmbissi 2001 KSA/East 384 _ _ 18 4.7 _ _ _ _ _ _ 
(103
) 
Al-Khunaizi 2003 KSA/East 37 _ _ _ _ _ _ 6 16.2 _ _ 
(101
) 
Saxena 2003 KSA/East 196 _ _ _ _ _ _ 81 41.3 _ _ 
(102
) 
Saxena 2003 KSA/East 208 _ _ _ _ 79 38 _ _ _ _ 
(108
) 
Saxena 2004 KSA/East 205 _ _ _ _ 78 38 _ _ _ _ 
(107
) 
Saxena 2004 KSA/East 198 86 43.4 _ _ _ _ _ _ _ _ 
(111
) 
Abdelrahman 2006 KSA/East 256 18 7 _ _ _ _ _ _ _ _ 
(83) Al-Nasser 1992 KSA/South 66 _ _ _ _ _ _ 30 45.5 50 75.8 
(90) Al-Homrany 1997 KSA/South 270 13 4.8 _ _ _ _ _ _ _ _ 
(91) Kumar 1997 KSA/South 47 _ _ _ _ _ _ 24 51.1 _ _ 
(120
) 
Khan 2002 KSA/South 67 _ _ _ _ _ _ 31 46.3 _ _ 
(80) Hussein 1990 KSA/West 205 23 11.2 _ _ _ _ _ _ _ _ 
(85) Hussein 1994 KSA/West 325 30 9.2 _ _ _ _ 46 14.2 47 14.5 
 
TB= Tuberculosis, NCOSA= Nasal carriage of Staphylococcus aureus, HCV= Hepatitis C Virus, HBV= Hepatitis B 
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Table 3.15. Summary of reported other co-morbid conditions in the ESRD population 
Ref Author Year Location 
Sample 
size 
Bone disease Depression Anaemia GIA RLS MN Liver disease 
No. % No. % No. % No. % No. % No. % No. % 
(78) Al-Haddad 2003 Bahrain 45 _ _ 21 46.7 _ _ _ _ _ _ _ _ _ _ 
(79) Al-Suwaida 2007 GCC 563 _ _ _ _ 190 33.7 _ _ _ _ _ _ 111 19.7 
(116) Al-Jahdali 2009 KSA/Riyadh, Jeddah 114 _ _ _ _ _ _ _ _ 57 50 _ _ _ _ 
(104) Al-Mueilo 2004 KSA/East 54 _ _ _ _ _ _ 49 90.7 _ _ _ _ _ _ 
(85) Hussein 1994 KSA/West 325 94 28.9 _ _ _ _ _ _ _ _ _ _ 28 8.6 
(98) Al-Homrany 2001 KSA/South 54 _ _ 32 59.3 _ _ _ _ _ _ _ _ _ _ 
(94) Mitwalli 1998 KSA/Centre 57 40 70.2 _ _ _ _ _ _ _ _ _ _ _ _ 
(119) Al-Wakeel 2002 KSA/Centre 110 _ _ _ _ _ _ _ _ _ _ _ _ 30 27.3 
(113) Al-Shatwi 2007 KSA/Centre 61 _ _ _ _ 29 47.5 _ _ _ _ _ _ _ _ 
(117) Al-Saran 2009 KSA/Centre 200 _ _ _ _ _ _ _ _ _ _ 64 32 _ _ 
 
GIA= Gastrointestinal abnormalities, RLS= Restless leg syndrome, MN= malnutrition 
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Causes of mortality in ESRD patients 
Causes such as pulmonary oedema, ischemic heart disease, and myocardial infarction were 
grouped under one category, cardiovascular disease. Meta-analysis showed that the 
summarised estimate of cardiovascular disease is 44.76% (95%CI: 25.21%, 64.32%) with an I-
square of 93.2% [Figure 2.25], while cerebrovascular disease is 11.64% (95%CI: 1.48%, 
21.80%) with an I-square of 83.5% [Figure 2.26]. The summarised estimate of sepsis as a 
cause of death in ESRD patients is 19.61% (95%CI: 12.60%, 26.62%) with an I-square of 35.8% 
[Figure 2.26]. Malfunction of dialysis access was only reported in one study as a cause of 
death in ESRD patients at 32.43% (95%CI: 18.01%, 49.78%) (103). Pulmonary disease as a 
cause of death was reported in two studies; one reported the percentage of pulmonary 
disease as a cause of death at 4.35% (95%CI: 0.56%, 14.84%) (85), and the other reported the 
percentage as 9.43% (95%CI: 3.13%, 20.66%) (95). Gastrointestinal bleeding was reported as a 
cause of death in two studies as 4.3% (95%CI: 0.53%, 14.84%) (85), and 10.81% (95%CI: 
3.02%, 25.42%) (103) [Table 2.16]. 
 
Figure 3.25. Forest plot showing the pooled estimate of the prevalence of cardiovascular disease as a cause of 
death among patients with ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Figure 3.26. Forest plot showing the pooled estimate of the prevalence of cerebrovascular disease as a cause of 
death among patients with ESRD in the countries of the GCC. 
 
 
Figure 3.27. Forest plot showing the pooled estimate of the prevalence of sepsis as a cause of death among 
patients with ESRD in the countries of the GCC. 
NOTE: Weights are from random effects analysis
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Table 3.16. Summary of reported mortality causes among ESRD patients 
Ref Author Year Location 
Sample 
size 
CVD CVA Sepsis PI PE GIB MLG MODA 
Miscell-
aneous 
No. % No. % No. % No. % No. % No. % No. % No. % No. % 
(76) Shankuntala 1992 
UAE/Abu 
Dhabi 
38 24 63 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
(77) El-Reshaid 1994 Kuwait 95 57 60 2 2 23 24.2 _ _ _ _ _ _ _ _ _ _ 10 11 
(119) Al-Wakeel 2002 KSA/Centre 29 22 76 3 10 _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
(95) Al-Muhanna 1999 KSA/East 53 18 34 13 25 7 29 3 6 2 4 _ _ 5 9 _ _ 5 9 
(103) Al-Khunaizi 2003 KSA/East 37 5 14 _ _ _ _ _ _ _ _ 4 11 _ _ 12 32 _ _ 
(85) Hussein 1994 KSA/West 46 11 24 6 13 10 77 _ _ 2 4 2 4 _ _ _ _ 15 33 
 
CVD= Cardiovascular disease, CVA= Cerebrovascular accident, PI= Pulmonary infection, PE=Pulmonary embolism, GIB= Gastrointestinal Bleeding, MLG= Malignancy, 
MODA=Malfunction of dialysis access, Miscellaneous= road traffic accident, refused treatment, cardiac arrest, and unknown cause 
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Discussion 
This review gives an overview of the epidemiological pattern of ESRD in the countries of the 
GCC. The demographic distribution of ESRD patients in the countries of the GCC shows that the 
overall proportion of males (52%) with ESRD is slightly higher than females (48%), and that the 
age group with the highest prevalence is between 41 and 53 years old. This is because the 
prevalence of risk factors for ESRD among males is higher than females in the general 
populations in the world as in Saudi Arabia(121-123), which is where most of the included 
studies were conducted, while the middle-aged group constitutes the majority of the 
population, and elderly people (those aged >65) constitute only 3% (46). This clarifies why the 
proportion of elderly patients with ESRD was small in the studies included in this review. This 
finding is similar to the demographic distribution for dialysis population in Saudi Arabia that was 
reported by SCOT in 2011 (60). The most frequent type of RRT in the GCC countries is dialysis, 
particularly haemodialysis, which might be due to the low rate of renal transplantation or to 
insufficient organ donation to meet demand. Renal transplantation prevalence was reported in 
only five studies and ranged from 3.7% to 47.9% (76, 77, 85, 96, 119). While the SCOT 2011 
report shows that the number of kidneys transplanted from living donors is more than double 
the number of kidneys transplanted from deceased donors, the number of kidneys transplanted 
from living donors has been markedly increasing since 1979 in Saudi Arabia (60). 
The incidence, prevalence and mortality rate of ESRD in the GCC were not reported 
sufficiently in studies included in this review. All of the included studies reported the 
cumulative incidence rate, which does not show changes in the trend; the exception was one 
study that reported the mean annual growth rate in Gizan of 7.44% in the period from 1987 
until 2000 (96). However, two studies in this review that were conducted in Saudi Arabia in Al-
Madinah city show that the incidence had increased two-fold from 1988 to 2001 (86, 105); 
this implies that the incidence has been increasing gradually over time. Furthermore, the 
mortality rate among ESRD patients in this review varied widely between studies across the 
region that may relate to differing treatment practices between healthcare centres, which 
contribute to the variation in outcomes. In addition, it was difficult to track the trend of 
prevalence and mortality in this review because of gaps in the available data. However, SCOT 
data show that the mean annual growth rate of dialysis patients is around 8% (60), which may 
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imply that the prevalence of ESRD is increasing without taking into account the kidney 
transplant and mortality rate. The increasing size of the ESRD population who require RRT in 
the countries of the GCC might be due to multiple factors such as the population growth rate 
and the rapid socioeconomic development in these countries in recent decades, which has 
resulted in changing lifestyle and nutrition habits (50). This in turn, plays a role in changing 
the trend of the prevalence of non-communicable disease such as diabetes, which is the 
leading global cause of ESRD (42, 124). Many reports have shown evidence of increasing 
prevalence of the most common causes of ESRD in the GCC such as obesity, hypertension, 
and diabetes, where the prevalence of diabetes and hypertension is significantly higher in 
urban populations than rural populations (26, 121, 125). This supports the finding in this 
review that the prevalence of diabetic nephropathy and hypertensive nephropathy as a cause 
of ESRD tend to be higher in urban areas than rural areas. 
The findings in this review show that the leading cause of ESRD in the GCC was diabetic 
nephropathy (21%-31%), followed by GN (14%-23%) and hypertensive nephropathy (9%-19%). 
The prevalence of diabetic nephropathy has been increasing significantly over time, while the 
prevalence of GN has been decreasing over time. Furthermore, among all of the reported co-
morbid conditions in this review, hypertension was the most prevalent chronic condition 
among patients with ESRD in the countries of the GCC, and ranged between 50% and 84%. In 
addition, infectious diseases were also prevalent co-morbid conditions, of which HCV infection, 
which is associated with a high rate of chronic liver disease and cirrhosis (126),was the most 
prevalent among patients with ESRD in the countries of the GCC, particularly among 
haemodialysis patients, with a range from 24%-58%. This might be due to many factors, such 
as the effect of nurse understaffing, which means that the staff were not highly trained overall 
(106, 127-129). Other factors may increase the risk of HCV, such as the length of dialysis, or the 
number of blood transfusions that might have involved incomplete or absent anti-HCV 
screening of donated blood (130); also, diabetic patients and males are more likely to develop 
HCV (107-109, 127, 131-133). However, this review found that the prevalence of HCV has 
declined in recent decades, which is a similar finding to that reported in the SCOT report in 
2011 (60). 
Causes of mortality and hospitalisation among ESRD patients usually result from infectious 
diseases or complications of dialysis or chronic illness, as they may reflect the quality of 
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healthcare services or the severity of the chronic illness. The most frequent causes of death in 
ESRD populations in this review were cardiovascular disease (between 25% and 64% of deaths) 
and sepsis (13%-27%). Two of the studies included in this review reported the causes of 
hospitalisation. One study reported that the major cause of hospitalisation was cardiovascular 
disease followed by vascular access-related problems, while ischemic heart disease contributed 
to 19% of the total hospitalisation (119). Another study reported the main cause of 
hospitalisation as vascular access-related problems (34%) (110). However, one of the studies 
included in this review suggested that the optimisation of arteriovenous fistula (AVF) placement 
might be a preventative approach to reduce infections associated with vascular access 
problems among haemodialysis patients, such as Staphylococcus aureus infection, which can 
lead to septicaemia (102). This suggestion is supported by the National Kidney Foundation’s 
Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guideline for vascular 
access, where AVF is the most preferable type of permanent vascular access for HD patients, 
and is related to an improved quality of life and increased life expectancy in HD patients (134). 
Limitations 
This review includes gaps in the data that did not allow tracking the trends of the prevalence 
and incidence rate of ESRD and mortality rates among patients with ESRD. Furthermore, the 
majority of studies included in this review were concerned with the haemodialysis population, 
while there is no available data on either pre-emptive renal transplantation or elderly people 
receiving supportive care. In addition, this review is prone to selective bias in terms of 
excluding all of the patients who received dialysis for less than three months to exclude those 
patients with acute renal failure. This might have resulted in the exclusion patients with ESRD 
who did not survive for more than three months. Also, many of included studies did not report 
the relevant outcomes as primary outcomes. Although this review provided an overview 
regarding the burden of ESRD in the countries of the GCC, it was not able to provide accurate 
and updated estimates for each related outcome, and the majority of studies were given a low 
score in methodological quality assessment; this might have been because they were not well 
reported or lacked sufficient data. In addition, the heterogeneity between the studies, which 
was represented by the I-square value, was high in many estimates for relevant outcomes in 
this review. Therefore, the lack of a comprehensive national renal registry data or health 
information system in the countries of the GCC is a critical issue. These data aim to provide a 
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reliable and up to date source of health information to allow regular assessment for healthcare 
services. Sufficient information is supposed to be recorded for each ESRD patient, such as 
demographic and clinical characteristics, RRT, vascular access, primary causes of ESRD, co-
morbid conditions, laboratory tests, medications, hospitalisation, death event and cause of 
death. Each outcome must be recorded and dated by healthcare specialists according to 
standardised policies, especially in diagnostic procedures, as this review showed that between 
15% and 27% of the aetiology of renal disease was uncertain or unknown. 
Strengths 
This review included all of the epidemiological studies conducted in the GCC up until 2010 and 
presents adequate and comprehensive information based on epidemiological studies for 
multiple outcomes related to ESRD. It provides an evidence-based health policy of increasing 
the burden of ESRD, which helps public health planners and administrators to enable the 
prediction of healthcare trends and to allocate healthcare resources. Also, this review defines 
people at high-risk of developing ESRD in the countries of the GCC, namely those of middle 
age, who are diabetic or hypertensive. This emphasises the importance of developing 
preventative strategies such as regular screening for people at high risk to detect and manage 
CKD in the early stages, and to prevent or slow down its progression to ESRD. Those programs 
may be more cost effective in the future as they increase the early detection of CKD that may 
attribute to decrease the incidence of ESRD and the number of patients who need RRT (42, 
135, 136). Furthermore, this review records all co-morbid conditions and causes of death in 
ESRD patients in the GCC. This information is extremely valuable for policy makers to assess 
the current situation and to improve the quality of healthcare management in the countries of 
the GCC, whereas the quality of healthcare practice should be a target for healthcare 
providers, in order to improve the quality of life and life expectancy for patients with ESRD. 
Also, this review provides insight regarding the sources and quality of the current health 
information system in the GCC, and identifies priority areas for further healthcare 
management research. 
Comparisons 
By comparing this review with a similar publication that was undertaken for the countries of the 
Middle East which the countries of the GCC are a part of, it can be seen that both highlighted 
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that the incidence of ESRD is increasing substantially, and that diabetes is a dominant cause of 
ESRD (137). These findings are similar to those reported in the United States and Europe, where 
diabetes was found to be the predominant cause of ESRD (138-140). This review shows that the 
prevalence of diabetic nephropathy as a cause of ESRD in the countries of the GCC in the period 
2000-2010 was around 33%, which is higher than the reported prevalence of diabetic 
nephropathy in 2010 in the United Kingdom (26%), but lower than in the United States (54.5%) 
(141). This review indicates that hypertension is the commonest co-morbid condition in the 
ESRD population in the countries of the GCC, as outlined in the SCOT report (60); both reports 
are similar to that which was found in the countries that participate in Dialysis Outcomes and 
Practice Patterns Study Programs (DOPPS) (141). Furthermore, in comparing the findings of this 
review with the SCOT report, we found that the prevalence of HCV among ESRD patients in the 
countries of the GCC to be high: around 35% in the period between 2000-2010 in this review 
and 26% in the SCOT report in 2011; these results are higher than those reported in Europe 
(12%) and the United States (7%) (52, 142). The observed variation in outcomes between 
countries or healthcare centres suggests opportunities for improving healthcare management. 
Conclusion 
This review presents an evidence-based health policy of the increasing burden of ESRD in the 
countries of the GCC. This stressed the needs and the importance of preventative strategies 
for leading causes of ESRD, as this review explored the major causes of ESRD in these 
countries and the most frequent co-morbid conditions and causes of mortality among 
patients with ESRD. Accordingly, this review suggested that the dominant cause of ESRD in 
the GCC was diabetic nephropathy, that the most frequent co-morbid conditions were 
hypertension and HCV, and that the primary causes of mortality were cardiovascular disease 
and sepsis. These results identified priority areas for further researches to assess the quality 
of healthcare management consistently and provide an updated evidence-based health 
policy, which will help healthcare providers to choose the best intervention that will help to 
improve healthcare practice outcomes. Furthermore, this review highlights the need for 
health information systems to allow regular screening for those people at high risk and detect 
CKD in the early stages, to describe the epidemiological pattern of ESRD in the countries of 
the GCC, and to conduct further research for assessing the overall quality of healthcare 
management for patients with ESRD in the countries of the GCC. 
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CHAPTER 4 
Review of pre-end-stage renal disease care 
in the western region in Saudi Arabia 
Abstract 
Background 
Chronic kidney disease (CKD) has emerged as an important public health issue worldwide, as 
undiagnosed or late detection cases of CKD are associated with an increased incidence rate 
and burden of end-stage renal disease (ESRD). The risk factors for CKD have been increasing 
in the Saudi population. Consequently, the incidence of ESRD has increased substantially over 
the past three decades with very limited literature on the assessment of pre-ESRD nephrology 
care practices in Saudi Arabia. 
Aims 
To assess pre-ESRD care practices in Saudi Arabia by describing the preliminary indicators 
including: reason for referral to nephrology care, source of referral to nephrology care, 
duration of pre-ESRD care, and vascular access at the first dialysis; and primary causes of 
ESRD. Also, to investigate the potential factors that may be associated with late referral to 
nephrology care practices and its consequences. 
Methods 
A cross-sectional study was conducted in Al-Noor Kidney Centre and Jeddah Kidney Centre in 
the western region of Saudi Arabia. Participants were patients with ESRD on haemodialysis 
during 2011; all requested data were retrieved from medical records retrospectively. 
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Results 
Preliminary indicators of pre-ESRD care showed that a large proportion (47.6% (95%CI: 41.7%, 
53.5%)) of haemodialysis patients had not received pre-ESRD nephrology care; 50.6% (95%CI, 
45.6%, 55.6%) of patient referrals arrived from the emergency department and the 
predominant vascular access point for haemodialysis was initially a catheter in 88.3% (95%CI: 
84.5%, 91.3%) of patients. Endocrine, nutritional and metabolic diseases, and immune 
disorders were the principal reason for patient referral, occurring in 50.6% (95%CI: 45.1%, 
56.1%) of patients, followed by diseases of the circulatory system in 39.9% (95%CI: 34.6%, 
45.3%) of patients. The dominant causes of ESRD in the study sample were hypertensive 
nephropathy (55.8% (95%CI: 50.8%, 60.7%)) and diabetic nephropathy (24.6% (95%CI: 20.4%, 
29.1%)). Factors significantly associated with late referral to nephrology care practices were 
referral source (p-value<0.0001), reason for referral (p-value=0.005), and vascular access 
used at first dialysis (p-value<0.0001). Thus, the possibility of initiating haemodialysis with 
arterio-venous fistula (AVF) increased by 1% (95%CI: 1.00%, 1.02%; p-value=0.02) with each 
one month increase in pre-ESRD care; while patients who were referred from outpatient 
clinics were more likely to initiate haemodialysis with AVF compared with those who were 
referred from an emergency department (OR=3.99; 95%CI: 1.44, 11.02; p-value=0.008). 
Patients who were referred to nephrology care because of diseases of the circulatory system, 
as well as endocrine, nutritional and metabolic diseases, and immune disorders, were less 
likely to initiate haemodialysis with AVF compared with those who were referred because of 
diseases of the genitourinary system; (OR=0.19; 95%CI: 0.04, 0.89; p-value=0.03), (OR=0.11; 
95%CI: 0.02, 0.51; p-value=0.005) respectively. 
Conclusion 
This study provides evidence to support the need for improving the rate of referring patients 
with CKD at earlier stages to nephrology care in Saudi Arabia. Potential strategies could 
involve regular screening of high risk people, encouraging communication between 
healthcare practitioners, and education on the need to refer patients with CKD to nephrology 
care at earlier disease stages, and increasing patients’ awareness about their health 
conditions and the potential consequences of their kidney disease. 
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Background 
Chronic kidney disease (CKD) has emerged as an important public health issue worldwide, as 
undiagnosed or late detection cases of CKD are associated with an increased incidence and 
prevalence rate of end-stage renal disease (ESRD), and poor outcomes after initiating renal 
replacement therapy (RRT) (143-146). This increases the need for multidisciplinary 
management including financial and social support, and medical care (147). Pre-ESRD 
nephrology care, which is known as early referral of patients with CKD to specialised renal 
services, can help to preserve renal function and delay the progression of renal failure by 
preventing and managing the modifiable risk factors associated with CKD and treating 
secondary complications (35, 148) that including metabolic syndromes (149-151), and 
anaemia (152-155). 
Many studies have shown that a long duration of pre-ESRD nephrology care, which is the 
period between the first time the patient has been seen by a nephrologist and the first 
dialysis (148), has a significant effect on the quality of life and survival rate in patients with 
ESRD before and after initiating RRT (35, 145, 156-158). Improved detection of patients with 
CKD in its early stages can significantly reduce the risk of cardiovascular morbidity and its 
consequences such as hospitalisation and death (159-162). Besides, pre-ESRD nephrology 
care gives an adequate time to prepare patients for RRT, especially those patients who need 
to create vascular access for dialysis, as maturation of the arterio-venous fistula (AVF) takes 
from six to eight weeks, and helps to improve pre-emptive renal transplantation treatment 
which is required for at least one year in preparation (144, 148). The National Kidney 
Foundation - Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines recommend 
that preparation for RRT should start in CKD stage 4, when the estimated glomerular filtration 
rate (eGFR) is <30mL/min/1.73m2 (148). This gives time to choose and create a suitable 
dialysis access point, considering AVF as a modifiable risk factor for bacteraemia and 
mortality (163, 164), and avoids the need for a catheter as a temporary vascular access. These 
healthcare practices have a significant impact on improving the prognosis and quality of life 
among the dialysis population, (164-166) and reducing hospital utilisation and the costs of 
healthcare (167-170). 
In Saudi Arabia, the incidence and prevalence rate of RRT have increased substantially over 
the last three decades (60). Many reports have shown evidence for an increase in the 
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prevalence of the most common risk factors for CKD such as obesity associated chronic 
diseases (26, 49, 50), and metabolic disorders; this in turn increases the risk of developing 
cardiovascular diseases and diabetes (171, 172). Diabetic nephropathy is the leading cause of 
ESRD in Saudi Arabia (27, 60, 173). There is limited literature available for assessing the 
quality of pre-ESRD nephrology care in Saudi Arabia. Only two studies have been conducted 
to review pre-ESRD nephrology care based on a single centre experience in two different 
regions of Saudi Arabia; both used creatinine clearance as measurement for renal 
impairment, which might overestimate the GFR (174), at the time of referral to the 
nephrologist as an indicator for late referral to nephrology care (99, 175). Therefore, more 
indications of pre-ESRD nephrology care and its consequences need to be assessed to 
improve healthcare practice outcomes among patients with CKD. 
Aims and scope 
The primary aim of this study was to assess pre-ESRD care and to investigate the primary 
causes of ESRD in two of the most active Ministry of Health (MOH) hospitals in the western 
region of Saudi Arabia. Pre-ESRD nephrology care was reviewed based on describing multiple 
indicators including reasons for referral to nephrology care, referral source to nephrology 
care, pre-ESRD care period, and vascular access type at the first dialysis. The secondary aim 
was to investigate the potential factors that may be associated with late referral to 
nephrology care and its consequences. The results of this study may be valuable for providing 
evidence-based health policy for public health administrators and healthcare providers in 
Saudi Arabia to prepare a strategy to define and screen people at consistently high risk and to 
improve rates of early referral to nephrology care, both of which rely upon multidisciplinary 
demands. These healthcare practices should have a significant impact in the future in 
decreasing the incidence rate of ESRD, improving the prognosis and quality of life among 
patients with ESRD before and after initiating RRT, and reducing the burden of healthcare 
costs. 
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Methods 
Study design and setting 
A cross-sectional study was conducted in two large haemodialysis centres in the western 
region of Saudi Arabia: Alnoor Kidney Centre (AKC), Al Noor Specialist Hospital in the city of 
Makkah, and Jeddah Kidney Centre (JKC), King Fahad General Hospital in the city of Jeddah. 
Both are Ministry of Health Hospitals, and are therefore expected to have a similar quality of 
healthcare services. Data were obtained after applying for ethical approval from the Ministry 
of Health and General Directorate of Health Affairs in each city. 
Study population 
Inclusion criteria 
Participants were the prevalent patients with ESRD on regular haemodialysis during 2011. 
This haemodialysis population was chosen for two reasons: according to the Saudi Centre for 
Organ Transplantation report, they constitute the largest population among patients with RRT 
in Saudi Arabia (60); and it is easy to locate these patients and extract their medical history 
and follow-up retrospectively from medical records in dialysis centres, despite the lack of 
primary care networks and health information systems in Saudi Arabia. 
Exclusion criteria 
All visiting patients to dialysis centres, who did not have a documented medical history in 
their medical records, and patients with advanced malignancy were excluded. 
Data collection 
Electronic medical records were searched to identify all patients with ESRD on haemodialysis 
in 2011. The total number of patients on haemodialysis in AKC, Al-Noor Specialist Hospital in 
Makkah was 418, the corresponding number in JKC, King Fahad General Hospital in Jeddah 
was 634. A simple random sampling technique was used to select a sample of 69 patients 
from JKC because of time limitations; all patients from AKC were included except for 84 
visiting patients to the dialysis centre without a medical history who were excluded. The 
requested data, including demographic information, date first seen by a nephrologist, reason 
for referral to a nephrologist, referral source to nephrology care, date of first dialysis, vascular 
89 
access used at first dialysis, and causes of ESRD, were collected from medical records and 
stored in a customised Microsoft Office Access database. 
Statistical analysis 
Each patient’s age at the time of referral to nephrology care and during the pre-ESRD care 
period were calculated. The pre-ESRD care period was categorised as: 0 months, <6 months, 6-
12 months, and >12 months. Reasons for referral to nephrologists were classified using the 
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) and then 
grouped into the following categories: diseases of the genitourinary system including disorders 
of the urethra and urinary tract such as haematuria; diseases of the circulatory system 
including uncontrolled blood pressure; endocrine, nutritional and metabolic diseases and 
immune disorders including diabetic nephropathy, nephrolithiasis, disorders of fluid 
electrolyte such as hyperkalaemia and hyperphosphatemia, and unspecified disorders of 
metabolism; symptoms and signs indicating renal diseases including proteinuria, abnormal 
creatinine clearance, and eGFR<30; and not reported. Also, primary causes of ESRD were 
classified according to the ICD-9-CM and grouped into the following categories: diabetes, 
glomerulonephritis (GN), secondary GN/vasculitis, interstitial nephritis/pyelonephritis, 
hypertension/large vessel disease, cystic/hereditary/congenital diseases, neoplasms/tumours, 
and miscellaneous conditions. 
Data were analysed descriptively to identify the preliminary indicators of pre-ESRD care and 
to investigate the primary causes of ESRD. To examine uncertainty, 95% confidence intervals 
(CIs) were calculated for each outcome. A t-test for two independent samples was performed 
to examine the association between age at time of referral to nephrology care and sex. A chi-
squared or Fisher's exact test was performed to examine the relationship between the pre-
ESRD care period and factors that might contribute to late referral to nephrology care 
practice such as age, sex, referral source, reason for referral to nephrology care, and causes 
of renal disease; the relationship between the pre-ESRD care period and related healthcare 
practice outcomes such as the type of vascular access used at first dialysis was also examined. 
Logistic regression was performed to estimate the effect of potential predictors such as age, 
sex, referral source, reason for referral to nephrology care, period of pre-ESRD, and causes of 
renal disease, on the possibility of initiating haemodialysis with AVF as an access point. All 
analyses were performed using STATA 11. 
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Results 
Patients’ characteristics 
The total sample size was 403 haemodialysis patients, derived from two dialysis centres: 334 
from AKC and 69 from JKC [Figure 3.1]. Males constituted 57.3% of the study population; 
93.1% were Saudis. The mean age at time of referral to nephrology care was 44.3 years (± 
standard deviation (SD) 16.4 years). A t-test showed that there was no significant difference 
between the mean age for males (43.6) and females (45.4) at time of referral to nephrology 
care with a mean difference of 1.8 years (95%CI: -2.01, 5.8; p=0.18). The median period of 
dialysis care was 4.3 years (25%, 75% percentiles: 2.4, 8.9). A total of 27 patients in the study 
sample died, and 10 underwent renal transplantation in AKC during 2011. [Table 3.1] 
 
 
Figure 4.1. Explanation of how the study size was derived. 
AKC 
Total HD= 
418 
Male= 238 
Female= 180 
JKC 
Total HD= 
634 
Male= 329 
Female= 305 
Sample=334 
Male= 191 
Female= 143 
Sample= 69 
Male= 40 
Female= 29 
Total sample size= 403 
N= 84 
excluded 
Random 
sample was 
selected 
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Preliminary indicators of pre-ESRD care and primary causes of ESRD 
In the study sample, the most commonly reported reasons for referral to nephrology care 
were endocrine, nutritional and metabolic diseases (50.6%), followed by disease of the 
circulatory system (39.9%), symptoms and signs indicating renal function deterioration 
(5.9%), and diseases of the genitourinary system (3.6%). In 67 records, the reasons for referral 
were missing or not reported. Referral from the emergency departments for urgent dialysis 
served as the principal referral source (50.6%); other sources included outpatient clinics for 
renal care (27.8%), and different healthcare centres for dialysis (21.6%). The pre-ESRD care 
period ranged from 0 to 274 months with median 0.06 months (25%, 75% percentiles: 0, 4.7); 
there were 113 missing records. A total of 47.6% of haemodialysis patients had not received 
pre-ESRD nephrology care, 28.6% of patients had received care for less than six months, 6.9% 
received care between six and 12 months, and 16.9% received care for more than 12 months. 
The principal access point for first dialysis in the study sample was via a catheter (88.3%). 
Only 8.9% were initiated through an AVF, 2.5% were initiated with an arterio-venous graft 
and 0.3% were initiated with peritoneal dialysis. To avoid misinterpretation, the trend for AVF 
and catheter as vascular access at first dialysis was examined [Figure 3.2]. During the last 
decade, there has been no improvement in referring patients in order to create AVF before 
first dialysis, and no decrease in the number of patients who have started dialysis with a 
catheter. This suggests that the rate of early referral practice for patients with CKD at earlier 
stages to nephrology care has not improved in recent decades. The dominant cause of ESRD 
was hypertension/large vessel disease (55.8%) followed by diabetes (24.6%), 
cystic/hereditary/congenital disease (7.2%), GN (6.5%), interstitial nephritis or pyelonephritis 
(4.5%), and secondary GN/vasculitis (1%), with 0.5% unknown. [Table 3.2]. 
Factors associated with late referral to nephrology care 
There was no statistically significant association between pre-ESRD care period and age 
(p=0.06), sex (p=0.6), or causes of renal disease (p=0.94). The association between pre-ESRD 
care period and reason for referral to nephrology care was statistically significant (p=0.005), 
where the majority of patients across all reasons for referral had received no pre-ESRD 
nephrology care or had received care but for less than six months. There was a significant 
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association between pre-ESRD care period and referral source (p<0.0001), where patients 
with CKD who had not received pre-ESRD care were often referred from emergency 
departments for urgent dialysis. Consequently, there was a strong association between pre-
ESRD care period and vascular access used at first dialysis (p<0.0001), where a large 
proportion of the study sample had initiated dialysis with a temporal catheter [Table 3.3]. 
Predictors contributing to initiation of haemodialysis with AVF 
The relationship between initiation of haemodialysis with AVF and age and sex was not 
statistically significant even after adjusting for other predictors including period of pre-ESRD 
care, reason for referral to nephrology care, cause of renal disease, and referral source. 
However, there appeared to be a proportional relationship between pre-ESRD care period 
and initiating haemodialysis with AVF, where a one month unit increase in pre-ESRD care 
increased the opportunity of CKD patients initiating haemodialysis with AVF by 1%, even after 
adjusting for other predictors (OR (odds ratio)=1.01; 95%CI: 1.00, 1.02; p-value=0.02). Thus, 
patients who were referred from different healthcare centres for renal care tended to be 
around two times more likely to initiate haemodialysis with AVF compared with those who 
were referred from an emergency department, even after adjusting for other predictors, 
although this association was not statistically significant (OR=2.30; 95%CI: 0.50, 10.66; 
p=0.29); patients who were referred from outpatients clinics were around six times more 
likely to initiate haemodialysis with AVF compared with patients who were referred from 
emergency departments; but after adjusting for other predictors the chance in those patients 
decreased to around four times (OR=3.99; 95%CI: 1.44, 11.02; p-value=0.008). Also, there was 
a significant association between the reason for referral to nephrology care and initiating 
haemodialysis with AVF in the study sample. 
Those patients who were referred to nephrology care because of circulatory system diseases 
were 85% less likely to initiate haemodialysis with AVF compared with patients who were 
referred to nephrology care because of diseases of the genitourinary system; however, after 
adjusting for other predictors, they were 81% less likely to initiate haemodialysis with AVF 
(OR=0.19; 95%CI: 0.04, 0.89; p-value=0.03). The patients who were referred to nephrology 
care because of endocrine, nutritional and metabolic diseases were 93% less likely to initiate 
haemodialysis with AVF compared with patients who were referred to nephrology care 
because of diseases of the genitourinary system; after adjusting for other predictors, they 
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were 89% less likely to initiate haemodialysis with AVF (OR=0.11; 95%CI: 0.02, 0.51; p-
value=0.005). Also, patients who were referred to nephrology care for unknown reasons due 
to missing data, who had probably been referred from other healthcare centres, were 91% 
less likely (OR=0.09; 95%CI: 0.01, 0.76; p-value=0.03) to initiate haemodialysis with AVF 
compared with patients who were referred to nephrology care because of diseases of the 
genitourinary system. There was no significant association between initiating haemodialysis 
with AVF and causes of renal disease, despite patients who had ESRD because of diabetic 
nephropathy being 61% less likely to initiate haemodialysis with AVF (OR=0.39; 95%CI: 0.11, 
1.40; p-value=0.15) compared with those patients who had ESRD because of hypertensive 
nephropathy [Table 3.4]. 
?
Figure 4.2. Vascular access at first dialysis in recent decades. 
AVF= arterio-venous fistula 
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Table 4.1. Summary of patient characteristics  
Patient characteristics 
Outcome 
(N=403) 
Patient source 
Alnoor Kidney Centre 334 
Jeddah Kidney Centre 69 
Age at referral to nephrology care 
Mean (SD) 44.3 (16.4) 
Range (1.9, 89.7) 
Missing 113 
Sex (%) 
Male 231 (57.3) 
Nationality (%) 
Saudi 375 (93.1) 
Period of pre-ESRD care (months) 
Median (25%, 75% percentiles) 0.06 (0, 4.7) 
Range (0, 274.2) 
Missing 113 
Period of dialysis (years) 
Median (25%, 75% percentiles) 4.3 (2.3, 8.9) 
Range (0.01, 21.2) 
Missing  13 
Patient status during 2011 
Survived 366 
Died 27 
Renal transplanted 10 
 
SD= standard deviation. 
95 
Table 4.2. Distribution of preliminary indicators of pre-ESRD care and primary causes of ESRD 
Outcome 
Frequency 
(N=403) 
% (95% CI) 
Reason for referral to nephrology care 
Diseases of the genitourinary system 12 3.57 (1.9, 6.2) 
Diseases of the circulatory system 134 39.88 (34.6, 45.3) 
Endocrine, nutritional and metabolic diseases & immunity disorders  170 50.60 (45.1, 56.1) 
Symptoms and signs indicating renal diseases 20 5.95 (3.7, 9.0) 
Missing/not reported 67 - 
Referral source 
Emergency 204 50.62 (45.6, 55.6) 
Outpatient clinic 112 27.79 (23.5, 32.4) 
Other healthcare centres 87 21.59 (17.7, 25.9) 
Period of pre-ESRD care/month 
0 months (not receiving pre-ESRD care) 138 47.59 (41.7, 53.5) 
<6 months 83 28.62 (23.5, 34.2) 
6-12 months 20 6.90 (4.3, 10.5) 
>12 months 49 16.90 (12.8, 21.7) 
Missing/not reported 113 - 
Access used at first dialysis 
AVF 32 8.91 (6.2, 12.4) 
AVG 9 2.51 (1.2, 4.7) 
Catheter 317 88.30 (84.5, 91.3) 
PD 1 0.28 (0, 1.5) 
Missing/not reported 44 - 
Causes of ESRD 
Cystic/hereditary/congenital disease 29 7.2 (4.9, 10.2) 
Diabetes 99 24.6 (20.4, 29.1) 
Glomerulonephritis 26 6.5 (4.3, 9.3) 
Hypertension/large vessel disease 225 55.8 (50.8, 60.7) 
Interstitial nephritis/pyelonephritis 18 4.5 (2.7, 7) 
Secondary GN/vasculitis 4 1 (0.3, 2.5) 
Miscellaneous conditions  2 0.5 (0.1, 1.8) 
 
CI =confidence interval, AVF=arterio-venous fistula, AVG=arterio-venous graft, PD=peritoneal dialysis, 
GN=glomerulonephritis 
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Table 4.3. Relationship between pre-ESRD care periods and patient characteristics. 
Outcome 
Pre-ESRD care period 
Total (%) p-value 
>12m 6-12m <6m 0m 
Age at time of referral to nephrology care (years) 
<14.9 5 0 1 2 8 (2.76)  
15-29.9 11 3 16 24 54 (18.62)  
30-44.9 14 5 21 43 83 (28.62)  
45-59.9 15 5 28 46 94 (32.41)  
≥60 4 7 17 23 51 (17.59) 0.06 
Sex 
Female 20 8 27 57 112 (38.62)  
Male 29 12 56 81 178 (61.38) 0.61 
Referral source 
Emergency department 7 6 36 108 157 (54.14)  
Other healthcare centre 11 5 11 17 44 (15.17)  
Outpatient clinic 31 9 36 13 89 (30.69) <0.0001 
Reason for referral to nephrology care 
Diseases of the genitourinary system 4 4 2 1 11 (4.37)  
Diseases of the circulatory system 12 4 31 39 86 (34.13)  
Endocrine, nutritional and metabolic diseases & 
immunity disorders 
19 11 41 69 140 (55.56)  
Symptoms and signs indicating renal diseases 2 0 4 9 15 (5.95) 0.005 
Causes of ESRD 
Cystic/hereditary/congenital disease 5 1 6 9 21 (7.24)  
Diabetes 13 7 23 31 74 (25.52)  
Glomerulonephritis 5 1 5 13 24 (8.28)  
Hypertension/large vessel disease 25 11 46 74 156 (53.79)  
Interstitial nephritis/pyelonephritis 1 0 3 7 11 (3.79)  
Secondary GN/vasculitis 0 0 0 2 2 (0.69)  
Miscellaneous conditions  0 0 0 2 2 (0.69) 0.94 
Access used at first dialysis 
AVF 14 3 10 0 27 (9.31)  
AVG 2 0 3 3 27 (2.76)  
Catheter 32 17 70 135 254 (87.59)  
PD 1 0 0 0 1 (0.34) <0.0001 
 
HD=haemodialysis, AVF=arterio-venous fistula, AVG=arterio-venous graft, PD=peritoneal dialysis, 
GN=glomerulonephritis 
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Table 4.4. Relationship between initiating haemodialysis with AVF as outcome and different patient 
characteristics. 
Predictor 
Unadjusted OR 
(95% CI) p-value 
Adjusted OR* 
(95% CI) p-value 
(N=403) (N=275) 
Age at time of referral to nephrology care 
Per a year unit 0.99 (0.96, 1.01) 0.29 1.01 (0.97, 1.04) 0.70 
Sex 
Female 1 _ 1 _ 
Male 1.17 (0.55, 2.48) 0.68 1.15 (0.46, 2.92) 0.76 
Referral source 
Emergency department 1 _ 1 _ 
Other healthcare centre 2.02 (0.62, 6.59) 0.24 2.30 (0.50, 10.66) 0.29 
Outpatient clinic 6.31 (2.57, 15.50) <0.0001 3.99 (1.44, 11.02) 0.008 
Period of pre-ESRD care 
Per month unit 1.01 (1.005, 1.02) 0.002 1.01 (1.001, 1.02) 0.02 
Reason for referral to nephrology care 
Diseases of the genitourinary system 1 _ 1 _ 
Diseases of the circulatory system 0.15 (0.04, 0.57) 0.005 0.19 (0.04, 0.89) 0.03 
Endocrine, nutritional and metabolic diseases & 
immunity disorders 
0.07 (0.02, 0.28) <0.0001 0.11 (0.02, 0.51) 0.005 
Symptoms and signs indicating renal diseases 0.16 (0.02, 1.06) 0.06 0.28 (0.03, 2.24) 0.23 
Missing/not reported 0.07 (0.01, 0.36) 0.002 0.09 (0.01, 0.76) 0.03 
Causes of ESRD 
Hypertension/large vessel disease 1 _ 1 _ 
Diabetes 0.50 (0.18, 1.38) 0.18 0.39 (0.11, 1.40) 0.15 
Glomerulonephritis 1.15 (0.32, 4.17) 0.83 1.15 (0.21, 6.32) 0.87 
Cystic/hereditary/congenital disease 0.70 (0.15, 3.18) 0.65 0.47 (0.07, 3.07) 0.43 
Interstitial nephritis/pyelonephritis 0.60 (0.07, 4.81) 0.63 _ _ 
Miscellaneous conditions _ _ _ _ 
 
OR= odds ratio, CI=confidence interval, HD=haemodialysis, AVF=arterio-venous fistula 
*Adjusted for age, sex, referral source, period of pre-ESRD care, reason of referral to nephrology care, and causes 
of ESRD. 
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Discussion 
In Saudi Arabia, the prevalence of risk factors for CKD has risen steadily in recent decades 
with a corresponding rise in the incidence and prevalence of RRT. In this study, pre-ESRD care 
and its consequences, and the primary causes of ESRD were reviewed to provide evidence of 
the quality of healthcare management services before initiating dialysis. The findings related 
to indicators of pre-ESRD nephrology care in this study show that around 41.7%-53.5% of 
haemodialysis patients had not received any renal care before initiating dialysis, and around 
23.5%-34.2% had received care but for less than six months. This means the risk of morbidity 
and mortality is increased in these patients, and there is a reduced chance for patients to take 
part in clinical decisions regarding RRT options. Also, this suggests that there is inadequate 
time to provide a pre-dialysis educational programme and psychological preparation for 
patients with CKD, and inadequate time to create a suitable point for permanent vascular 
access to be used at first dialysis (156, 176-179). This resulted in around 45.6%-55.6% of CKD 
patients, who progressed to ESRD, being referred from emergency departments for urgent 
haemodialysis. This in turn led to around 84.5%-91.3% of patients with ESRD having to initiate 
haemodialysis with a temporary catheter, which is associated with an increased risk of access 
complications and mortality (164, 166, 169, 180, 181), and only around 6.2%-12.4% of 
patients having initiated haemodialysis with AVF. However, the NKF-KDOQI and the Renal 
Association Clinical Practice (RACP) Guidelines on Vascular Access for Haemodialysis 
recommend that 65% of all incident haemodialysis patients should initiate dialysis with AVF 
(182, 183). Furthermore, the trend of increasing incidence of haemodialysis patients with AVF 
has not shown any improvement in recent decades, which implies that the rate of referral of 
patients with CKD at earlier stages to nephrology care has not been improved, or that 
patients might have been referred to nephrology care but they were not educated enough 
about their health condition and its consequences. Although the rate of progression to ESRD 
for some patients with CKD is unpredictable making timing of access placement difficult, the 
RACP guidelines recommend that AVF should be placed at a minimum of three months before 
the expected day of initiating haemodialysis and probably not more than one year (183). 
Moreover, this study found that many of the patients (45.1%-56.1%) were referred to nephrology 
care because of endocrine, nutritional, and metabolic diseases and immunity disorders; and 
34.6%-45.3% were referred because of uncontrolled blood pressure. The majority of those 
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patients had received no nephrology care or the period of care was less than six months, while 
the dominant causes of ESRD were hypertensive nephropathy (50.8%-60.7%) and diabetic 
nephropathy (20.4%-29.1%). This implies that the detection and management of the risk factors 
for CKD including diabetes and hypertension needs to be improved in Saudi Arabia. NKF-KDOQI 
guidelines states that adverse outcomes of CKD, such as loss of kidney function, kidney failure, 
and cardiovascular disease, can be prevented or delayed by detecting and treating CKD at earlier 
stages. This can be done through routine laboratory measurements and eGFR for patients at high 
risk such as those diagnosed to have hypertension, diabetes, or dyslipidemia, particularly those 
with an eGFR of less than 60mL/min/1.73m2. However, declining eGFR is associated with multiple 
complications such as hypertension, anaemia, malnutrition, neuropathy, and bone disease. All 
these complications can be treated at earlier stages of CKD (35, 184, 185). 
Limitations 
Due to time limitations for collecting data, the lack of a comprehensive national health 
information system in Saudi Arabia, and some patients being referred from one healthcare centre 
to another, the laboratory measurements for renal function deterioration and eGFR were not 
usually available at the time of referral to nephrology care in many medical records and the 
reason for referral was often insufficiently explained. Furthermore, eGFR could not be calculated 
to determine at which CKD stage the patient had been referred to nephrology care due to missing 
or unreported information. The Modification of Diet in Renal Disease (MDRD) study equation to 
estimate GFR requires taking into account serum creatinine concentration, age, sex, race, and 
body mass index (35, 174). Therefore, the preliminary indicators for pre-ESRD nephrology care 
were used in this study for detecting late referral to nephrology care. There is a potential 
selection bias in terms of the study population due to focusing on haemodialysis patients only. 
Patients with ESRD who initiated RRT with peritoneal dialysis or had pre-emptive renal 
transplantation would have been referred to nephrology care at an early stage and received 
multidisciplinary pre-ESRD education. However, no data were available in the literature on the 
rate of initiating RRT with peritoneal dialysis or pre-emptive renal transplantation in Saudi Arabia. 
Strengths 
The indications of pre-ESRD nephrology care in this study provide evidence for public health 
administrators and healthcare providers in Saudi Arabia to develop multidisciplinary strategies 
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for improving pre-ESRD nephrology care practice and its outcomes. This study demonstrates 
that the majority of patients with CKD received no pre-ESRD care or they received less than six 
months of care across all reasons for referral, and therefore most patients with ESRD were 
referred from emergency departments for urgent haemodialysis and initiated dialysis with a 
catheter. Another screening study for CKD, conducted in Riyadh City in Saudi Arabia using eGFR 
and laboratory measurements to detect CKD in the general population, showed that around 7% 
of patients with CKD were not aware of their kidney status, 32% had known that they had 
protein or blood in their urine, and 11% had known that they had kidney stones, but it was not 
mentioned whether they were followed up by nephrology care services (135). This reflects 
delayed referral to nephrology care from other services such as primary care, diabetology, and 
cardiology. Also, where a strong primary healthcare network and health information system is 
absent, this might reflect that there are many individuals with CKD and its risk factors such as 
diabetes, hypertension, and cardiovascular disease who are undiagnosed in the general 
population or who have been diagnosed but not followed up consistently, which may explain 
why the majority of these individuals are not referred to nephrology care in the early stages of 
their disease and suddenly progress to ESRD and require urgent dialysis. Therefore, developing 
strategies to improve the rate of early referral should firstly involve regular screening to detect 
and manage the risk factors for CKD and CKD in the early stages; this cannot be done efficiently 
without a comprehensive health information system. Secondly, nephrology departments in 
healthcare centres should organise campaigns to educate healthcare practitioners including 
family physicians, diabetologists, cardiologists and internists about the necessity to refer 
patients with CKD to nephrology care at earlier stages of their illness. Thirdly, improved 
communication channels are required between healthcare practitioners, as well as defined 
accurate criteria as to when to refer patients with CKD to nephrology care using a standardised 
tool (144, 186). Fourthly, healthcare practitioners and social workers should organise 
programmes to increase patients’ awareness about their health status and potential 
complications. Finally, patients at high risk of ESRD should be trained to better self-manage and 
be educated about the options of RRT (187). Thus, the rate of referral of patients with CKD at 
earlier stages to nephrology care and its outcomes should be improved. 
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Comparisons 
By comparing the findings of this study with similar publications that were conducted in Saudi 
Arabia which used the level of serum creatinine clearance at time of referral to nephrology 
care to indicate late referral (99, 175), all studies suggested that healthcare practitioners 
should be aware about when they have to refer patients with CKD to nephrology care, in 
order to provide optimal pre-ESRD care. 
Conclusion 
This study provides evidence about the current status of pre-ESRD care in Saudi Arabia and 
suggests that the rate of early referral of patients with CKD to nephrology care must be 
improved in order to prevent or delay the progression of renal disease to ESRD. 
Communications between healthcare practitioners, and collaborations between primary and 
secondary healthcare professionals should be encouraged, to provide optimal pre-ESRD care 
including health education for patients about their illness and its consequences, giving 
patients the chance to consider and decide between RRT options, and allow time to create a 
permanent vascular access point for dialysis. Further prospective studies are needed to 
evaluate pre-ESRD care practice and its outcomes in order to implement the best intervention 
that will help to improve pre-ESRD care practice outcomes in Saudi Arabia. 
 
102 
CHAPTER 5 
Review of the indications for hospitalisation among 
haemodialysis patients in Saudi Arabia 
Abstract 
Background 
The high cost of hospitalisation for haemodialysis patients has become a public health 
concern because increases in the haemodialysis population together with escalating 
healthcare costs are not sustainable worldwide. In Saudi Arabia, the haemodialysis population 
has increased continuously in the last three decades with a high prevalence of co-morbid 
conditions and complications that are related to haemodialysis procedures. The indications 
for hospitalisation usually reflect either the quality of healthcare services, or the severity of 
patients’ co-morbid conditions. 
Aims 
This study was conducted to review the indications for hospitalisations which are associated 
with an increased cost of healthcare and reflect the severity of co-morbid conditions by 
investigating; (I) the primary causes for hospital admissions, (II) the primary causes for 
hospital admissions which are associated with an increase in length of stay in hospital, (III) 
the potential factors that might increase the number of hospital admissions among 
haemodialysis patients. 
Methods 
A retrospective cohort study was conducted in the Alnoor Kidney Centre in Al Noor Specialist 
Hospital, Makkah City, Saudi Arabia, which is a Ministry of Health hospital. Participants were 
prevalent patients with end-stage renal disease on regular haemodialysis in 2011, who had 
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received haemodialysis for more than three months. Each patient had been followed-up 
retrospectively, from the first date of initiating haemodialysis to the end of 2011. 
Results 
The most common reasons for hospitalisation among haemodialysis patients were diseases of 
the genitourinary system (40.1%; 95% CI: 35.7%, 44.6%), diseases of the circulatory system 
(22.6%; 95% CI: 19%, 26.6%), vascular access (19.5%; 95% CI: 16.1%, 23.4%), infectious 
diseases (9%; 95% CI: 6.6%, 12%), and endocrine and metabolic diseases (7.4%; 95% CI: 5.2%, 
10.1%). The primary reason for hospital admissions associated with increases in the length of 
stay in hospital, were diseases of the circulatory system (which increased hospital bed days by 
70%; 95% CI: 11% to 161%; p-value=0.01 compared to all other reasons). The risk factors that 
increased the rate of hospital admissions per patient-year at risk were increasing age 
(IRR=1.02; 95% CI: 1.01, 1.03; p-value=<0.0001); receiving haemodialysis through a catheter 
compared to arterio-venous fistula (IRR=2.55; 95% CI: 1.14, 4.97; p-value=0.0009); and 
diabetes as a cause of renal disease compared to hypertension (IRR=1.84; 95% CI: 1.29, 2.63; 
p-value=0.001). 
Conclusion 
Indications for hospitalisation and consequences of practices related to hospitalisation for 
haemodialysis patients should be studied in further researches to provide a comprehensive 
evidence-based health policy for haemodialysis patients in Saudi Arabia. 
Background 
The high cost of hospitalisation for haemodialysis patients has become a public health 
concern (188, 189) because an increase in the haemodialysis population together with 
escalating healthcare costs are not sustainable worldwide (139, 190, 191). The United States 
Renal Data System (USRDS) report highlighted that the rates of hospital readmissions for end-
stage renal disease (ESRD) patients are twice those in the general Medicare population (192). 
Patients with chronic kidney disease (CKD) in late stages are often hospitalised with general 
medical problems, especially those patients who have reached the end-stage of renal failure 
and are receiving regular haemodialysis in dialysis centres (193-195). Patients on 
haemodialysis require more resources than patients on peritoneal dialysis or with renal graft 
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need, especially during the first year of dialysis treatment; these resources include vascular 
surgery, radiology, physician cost, and hospitalisation (169, 188, 196-199). 
In Saudi Arabia, the incidence and prevalence of the renal replacement therapy (RRT) 
population have been increasing continuously in the last three decades with a high 
prevalence of co-morbid conditions (60, 200) and complications related to ESRD (27, 173). 
The most common method for treating patients with ESRD in recent decades has been 
haemodialysis, which accounts for just over half of the RRT population. The Ministry of Health 
(MOH) in Saudi Arabia incurs the vast majority of haemodialysis care costs, and provides 
around two-thirds of haemodialysis facilities. Although the ESRD population accounted for 
only 0.08% of the total Medicare population in Saudi Arabia in 2008, it is estimated that the 
healthcare costs associated with those patients were around 3.8% of the total MOH 
expenditure (27). In the United States, the ESRD population accounts for 0.5% of the total 
Medicare population, but the cost of ESRD care contributes to 5% of Medicare expenses 
(201); hospitalisation accounts for around 41% of the total ESRD care costs (202); and in the 
period between 1999 and 2004, the cost of ESRD care had risen to 6.7% with a corresponding 
increase in the ESRD population of 0.03% in 2004 (139). 
In order to provide comprehensive renal care services for patients on haemodialysis, a study 
demonstrated that the risk of readmission, length of stay in hospital, and the average cost of 
haemodialysis care tended to be lower for patients under the care of nephrologists compared 
to internists (189). The British Renal Society (BRS) National Renal Workforce Planning Group 
(2002) recommended that one whole-time equivalent renal physician is required for 75 to 
100 patients on RRT (203), while in Saudi Arabia one consultant nephrologist will be required 
for 234 patients on RRT by 2015 (27). Furthermore, patients with ESRD who had received pre-
ESRD care by nephrologists before initiating haemodialysis had a better outcome throughout 
haemodialysis with a reduced risk of hospitalisation and mortality compared to those patients 
who had not received nephrology care (170, 204-206). However, in Saudi Arabia, a large 
proportion of haemodialysis patients do not receive pre-ESRD care (99). 
The risk of hospitalisation increases among patients on haemodialysis due to complications of 
either haemodialysis (207, 208) or haemodialysis vascular access (209, 210), with a high 
prevalence of co-morbid conditions particularly diabetes (211) and cardiovascular diseases  
(212-214). The type of vascular access used in the dialysis process makes a significant 
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contribution to prognosis and quality of life (215-220). Many studies have shown that using a 
catheter at the initiation of haemodialysis or throughout the time on haemodialysis increases 
the risk of hospitalisation, particularly due to catheter related infection (221, 222). 
Conversions from catheter to arteriovenous fistula (AVF) have lowered the risk of 
hospitalisation among haemodialysis patients (164, 223-226). In Saudi Arabia, there is limited 
literature on studies of the risk of hospitalisation among haemodialysis patients particularly 
that associated with vascular access practice patterns. A few studies conducted in different 
areas of Saudi Arabia have shown that a large proportion of incident ESRD patients initiated 
haemodialysis treatment with a temporary catheter as a result of a late referral to nephrology 
care, a practice which is associated with increased morbidity and mortality (227, 228), and 
increased costs of healthcare. 
Diabetes is a costly condition and a substantial amount of money is spent annually worldwide 
to treat diabetes complications such as diabetic nephropathy and coronary artery disease, 
while a large proportion of the total cost is spending for hospitalisation (115, 229). Diabetic 
nephropathy is a common and often severe complication among diabetic patients; it is also 
related to an increased economic burden of ESRD care (211, 230, 231). Several studies have 
shown that age and diabetes are major risk factors for coronary artery disease (232-234), 
which is a major cause of cardiac hospitalisation and death among haemodialysis patients 
(205, 235). The National Kidney Foundation Kidney Disease Outcomes Quality Initiative 
(NKF/KDOQI) and the American Heart Association have stated that patients with CKD are 
considered to be in the highest risk group for cardiovascular disease events compared to the 
general population (35, 236), particularly coronary artery disease which is a major cause of 
cardiac hospitalisation and death among haemodialysis patients (205, 235). Saudi Arabia is 
one of the leading countries for diabetes prevalence in the world (237, 238) and therefore, 
diabetic nephropathy contributes significantly to renal disease, as the reported incidence of 
ESRD due to diabetic nephropathy in Saudi Arabia is also one of the highest in the world (27, 
60, 115, 200).        
The indications for hospitalisation among haemodialysis patients usually reflect either the 
quality of healthcare services, or the severity of patients’ co-morbid conditions, which may be 
associated with increasing hospital utilisation and healthcare costs. Only two studies in the 
literature have reported the period prevalence of the primary reasons for hospitalisation 
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among the haemodialysis population in Saudi Arabia. The first study conducted in Riyadh City 
reported cardiovascular disease as the primary reason for hospitalisation, followed by 
vascular access complications and infections (115). The second study conducted in Al-
Madinah City reported vascular access related problems as the primary reason, followed by 
infectious disease and cardiovascular disease (38). Neither study reported the risk factors that 
might increase the rate of hospital admissions or the length of stay in hospital per patient-
year on haemodialysis, which are usually reflections of the severity of patients’ co-morbid 
conditions and the quality of healthcare services. 
Aims and scope 
This study was conducted in one of the most active MOH hospitals in Makkah City in Saudi 
Arabia. The aims were to review the primary reasons and other indications for hospital 
admissions among patients with ESRD on haemodialysis. This would provide evidence-based 
health policy that may help to improve the quality of healthcare services where possible and 
meet the increasing demand for healthcare services among haemodialysis patients in Saudi 
Arabia. I also aimed to identify the priority areas for further healthcare services research that 
may help to reduce the rate of admission and length of stay in hospital in the future. The 
review of indications for hospital admission among haemodialysis patients, were performed 
by investigating the following: 
● The primary reasons for hospital admissions among patients with ESRD after starting 
haemodialysis 
● The reasons for hospital admissions associated with an increase in the length of stay in 
hospital. 
● The risk factors associated with an increase in the rate of number of hospital admissions 
after starting haemodialysis 
Methods 
Study design and setting 
A retrospective cohort study was conducted in the Alnoor Kidney Centre (AKC) in Al Noor 
Specialist Hospital, which is the largest Ministry of Health Centre in Makkah City in the 
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western region of Saudi Arabia. Data were obtained after applying for ethical approval from 
the Ministry of Health and General Directorate of Health Affairs in Makkah. 
Study population 
Inclusion criteria 
Participants were prevalent patients with ESRD on regular haemodialysis in 2011, who had 
received haemodialysis for more than three months. Each patient had been followed up 
retrospectively since the day after the first date of initiating haemodialysis until the end of 
2011. 
Exclusion criteria 
All visiting patients to the dialysis centre who did not have a documented medical history in 
medical records and patients with advanced malignancy were excluded. 
Data collection 
Electronic medical records were searched to identify all patients with ESRD on haemodialysis 
in 2011. The total number of patients on haemodialysis was 418. A further 84 patients visiting 
the dialysis centre without a medical history and 16 patients who had received haemodialysis 
for less than three months were excluded. 
The requested data including demographic information (age at onset of dialysis, sex, 
nationality), date of starting dialysis, patient status throughout 2011 (survived, renal 
transplant, died), causes of renal disease (diabetic nephropathy, hypertensive nephropathy, 
glomerulonephritis, other), vascular access (access type at first dialysis, access type during 
follow-up), co-morbid conditions (diabetes, hypertension, ischaemic heart disease, congestive 
heart failure, cerebrovascular disease, peripheral vascular disease, pulmonary disease, 
neurologic disease, gastrointestinal bleeding, hepatitis B virus (HBV), hepatitis C virus (HCV), 
catheter related infection), limitation in physical motion, ever received blood transfusion, and 
hospitalisation (causes of admission, dates of admission and discharge) were collected from 
medical records and stored in a customised Microsoft Office Access database. 
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Statistical analyses 
The total number of hospital admissions (excluding admissions on the day that haemodialysis 
was started) and the time on haemodialysis in years were calculated for each patient, and the 
length of stay in hospital was calculated for each hospitalisation. Admissions for less than one 
night observation were excluded from the analysis. The primary causes for hospital 
admissions were classified using ICD-10 codes updated in 2011, and were grouped into the 
following diagnostic categories for analyses: non-infectious diseases including anaemia, 
diseases of the musculoskeletal system, diseases of the digestive system, endocrine and 
metabolic diseases, diseases of the nervous system, diseases of the respiratory system, 
diseases of the genitourinary system, diseases of the circulatory system, diseases of the skin, 
vascular access, trauma or injury related conditions, and miscellaneous; and overall infectious 
diseases including sepsis, infections of the skin and subcutaneous tissue, infectious 
arthropathies, respiratory infectious disease, other infectious disease, and viral infection. 
[Appendix C] 
Data were analysed descriptively to describe patients’ characteristics, co-morbid conditions, 
and the distribution of the most frequent causes of hospital admissions after starting 
haemodialysis in the study sample. Negative Binomial regression was used among patients 
who were hospitalised at least once, clustered hospital admissions data by patients’ identity 
numbers to investigate which primary reasons for hospital admissions were associated with 
the greatest number of hospital bed days per patient-year on haemodialysis. This is adjusted 
for patients’ characteristics at onset of haemodialysis such as age, sex, and causes of renal 
disease. Negative Binomial regression was also used amongst all patients to investigate the 
risk factors associated with an increase in the number of hospital admissions during time on 
haemodialysis, clustered by patient. This estimates the IRR of the number of hospital 
admissions per patient-year at risk for vascular access type during follow-up, and for causes of 
renal disease, adjusted for age, and sex. An equivalent model was created to examine the 
effect of vascular access type at start of dialysis, with the same covariates. All analyses were 
performed using STATA 11 (StataCorp, College Station, TX, USA). 
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Results 
Patients characteristics 
The total number of patients on regular haemodialysis was 318: 208 patients were 
hospitalised at least once, and 110 patients did not have any reported hospitalisation in Al 
Noor Specialist Hospital [Figure 4.1]. The median period of haemodialysis care (period of 
follow-up) was 4.3 years (25%, 75% percentiles: 2.4, 8.7), and around 8.2% of patients 
(26/318) had received haemodialysis for one year or under. The study sample was composed 
of 58.2% males and 93.7% Saudis. The mean age at onset of dialysis was 45.6 (± standard 
deviation (SD)=16.9) years. The dominant cause of renal disease in the study sample was 
hypertensive nephropathy (58.8%), followed by diabetic nephropathy (23.9%), and 
glomerulonephritis (4.1%). Haemodialysis was initiated through a catheter in 80.2% of 
patients; only 7.2% initiated haemodialysis through an AVF. In 2011, the type of vascular 
access appeared to have been replaced for the majority of patients after starting 
haemodialysis. The proportion of prevalent patients with a catheter decreased to around 
3.8%, and of those with an AVF, increased to around 95%. The prevalence of co-morbid 
conditions was high, particularly for diabetes (24.8%) and cardiovascular diseases including 
hypertension (75.2%), ischaemic heart disease (8.5%), congestive heart failure (6.3%), 
cerebrovascular disease (3.1%), and peripheral vascular disease (2.5%). The prevalence of 
HBV was 8.5%, while the prevalence of HCV was very high, around 47.5%. The prevalence of 
the occurrence of catheter related infection in the study population was 3.1%. A limitation in 
physical movement was found in 41.5% of patients, and 23% had received a blood 
transfusion. [Table 4.1] In 2011, 25 (7.9%) patients in the study sample died and 10 patients 
underwent renal transplantation although eight of them were rejected. The dominant causes 
of death were cardiovascular disease (7 patients) and sepsis (7 patients), followed by 
cerebrovascular accident (2 patients), cardiac arrest (2 patients), and death due to unknown 
or unreported reasons (7 patients). 
Primary reasons for hospital admissions and length of stay in hospital 
There were 486 recorded hospital admissions for 208 haemodialysis patients in the study 
sample. The length of stay in hospital ranged between one and 80 days per hospital 
admission with a median of three days per admission (25%, 75% percentiles: 2, 6). 
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Distribution of the primary reasons for hospital admissions 
The most frequent reasons for hospitalisation throughout the follow-up period in the study 
sample were diseases of the genitourinary system (40.1%), diseases of the circulatory system 
(22.6%), and vascular access (19.5%), followed by overall infectious diseases (9%), endocrine 
and metabolic diseases (7.4%), diseases of the digestive system (5.6%), diseases of the 
respiratory system (3.1%), diseases of the nervous system (1.8%), diseases of the 
musculoskeletal system (1.4%) and diseases of the skin (0.2%). 
Regarding diseases of the circulatory system, the most frequent cause of admissions was 
hypertensive disease (9.3%), followed by ischaemic heart disease (6.4%), other forms of heart 
disease (3.9%), cerebrovascular disease (1.8%), and peripheral vascular disease (1.2%). The 
majority of patients in the study sample initiated dialysis with a catheter as vascular access 
for haemodialysis which was often replaced by AVF during the first year of follow-up; 
therefore, the percentage of hospitalisations as a result of creating a permanent vascular 
access (14.8%) was higher than the percentage of hospitalisations due to complications (other 
than related infection) of vascular access (4.5%). For hospital admission due to overall 
infectious diseases, the most frequent admission was because of respiratory infectious 
diseases (3.5%), followed by infections of the skin and subcutaneous tissue (2.7%), and sepsis 
(1.4%). The highest percentage of hospital admissions due to endocrine and metabolic 
diseases was for metabolic disorders (5.1%), followed by disorders of the endocrine gland 
(1.6%) and diabetes mellitus (0.62%). [Table 4.2] 
Reasons for hospital admissions associated with an increase in the length of stay in hospital 
per patient-year on haemodialysis 
The adjusted ratios of mean number of bed days in hospital per patient-year on 
haemodialysis show that hospital admissions for diseases of the circulatory system increased 
the number of hospital bed days per patient-year on haemodialysis by 70% compared to 
other reasons for hospital admissions. Hospitalisations for diseases of the genitourinary 
system, for diseases of the nervous system, for trauma/ injury and for vascular access 
creation all resulted in lower mean hospital days per person-year on dialysis, compared to 
other reasons for hospitalisation. Note that vascular access procedures are usually required 
for haemodialysis patients during the first year of dialysis if the patient had haemodialysis 
initiated with a catheter [Table 4.3]. There was a proportional relationship between the 
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number of hospital bed days per patient-year on haemodialysis and patient age for all 
reasons for admission, and the adjusted rate of length of stay in hospital per patient-year at 
risk increased by around 2% per a year increase in patient age. Sex and causes of renal 
disease did not have any significant effect on the length of stay in hospital for any disease 
[Table 4.4]. 
Factors that increase the risk of hospital admissions per patient-year on 
haemodialysis 
The number of admissions for 318 patients in the study sample ranged between 0 and 17 
admissions per patient during the follow-up period, with median=1 hospital admission per 
patient (25%, 75% percentiles: 0, 2). The potential risk factors at baseline analysis, which 
might be associated with an increase in the number of admissions per patient-year on 
haemodialysis, were investigated. The findings from Model_2 show that the rate of the 
expected number of hospital admissions increased by 2% per patient-year at risk with a one 
year increase in age, while there was no significant effect for sex on the rate of number of 
admissions. Patients who received haemodialysis through a catheter during the follow-up 
period showed an increase in the rate of the expected number of hospital admissions by 2.55 
fold per patient-year at risk compared to those patients who received haemodialysis through 
an AVF. Patients who had ESRD because of glomerulonephritis or diabetic nephropathy also 
showed an increase in the rate of the expected number of admissions by 2.28-fold and 1.84-
fold respectively, compared to those patients who had ESRD because of hypertensive 
nephropathy, while the unadjusted IRR for the relationship between the number of 
admissions and glomerulonephritis as a cause of ESRD was not statistically significant. In 
Model_1, the estimated IRRs for hospital admissions show that the effect of age, sex, and 
causes of renal diseases are similar to those in Model_2. However, using a catheter at 
initiation of haemodialysis tends to increase the risk of hospital admission by 62% per patient-
year at risk, although this relation was not statistically significant. [Table 4.5] 
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Figure 5.1. Recruitment of study participants 
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Table 5.1. Characteristics of study participants 
Patient characteristics  Outcome (N=318 patients) 
Demographics 
Mean age in years (SD)  45.6 (±16.9) 
Male (%) 185 (58.18) 
Saudi (%) 298 (93.7) 
Access type at start of dialysis (%) 
AVF 23 (7.23) 
AVG 7 (2.2) 
Catheter 255 (80.19) 
PD 1 (0.31) 
Missing 32 (10.06) 
Access type during follow-up (%) 
AVF 302 (94.97) 
AVG 4 (1.26) 
Catheter 12 (3.77) 
Period of haemodialysis (years) 
Median (25%, 75% percentiles) 4.3 (2.4, 8.7) 
Cause of renal disease (%) 
Diabetes 76 (23.9) 
Glomerulonephritis 13 (4.09) 
Hypertension 187 (58.81) 
Other 42 (13.21) 
Comorbid conditions (%) 
Diabetes 79 (24.8) 
Hypertension 239 (75.2) 
Ischaemic heart disease 27 (8.5) 
Congestive heart failure  20 (6.3) 
Cerebrovascular disease 10 (3.1) 
Peripheral vascular disease 8 (2.5) 
Pulmonary disease 22 (6.9) 
Neurologic disease 11 (3.5) 
Gastrointestinal bleeding 3 (0.9) 
Hepatitis B virus 27 (8.5) 
Hepatitis C virus 151 (47.5) 
Catheter related infection 10 (3.14) 
Limitation in physical motion (%) 132 (41.51) 
Ever received blood transfusion (%) 73 (23) 
 
AVF=arteriovenous fistula, AVG=arteriovenous graft, PD=peritoneal dialysis 
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Table 5.2. Distribution of hospital admissions by diagnostic categories 
Cause of hospitalisation  
Frequency 
(N= 486 admissions) % (95% CI) 
Anaemia 8 1.65 (0.71, 3.22) 
Diseases of the circulatory system 110 22.63 (18.99, 26.62) 
Hypertensive disease 45 9.26 (6.83, 12.19) 
Ischaemic heart disease 31 6.38 (4.37, 8.93) 
Other forms of heart disease 19 3.91 (2.37, 8.93) 
Cerebrovascular disease 9 1.85 (0.85, 3.49) 
Vascular disease 6 1.23 (0.45, 2.67) 
Diseases of the digestive system 27 5.56 (3.69, 7.98) 
Diseases of the genitourinary system 195 40.12 (35.73, 44.63) 
Diseases of the musculoskeletal system 7 1.44 (0.58, 2.94) 
Diseases of the nervous system 9 1.85 (0.85, 3.49) 
Diseases of the respiratory system 15 3.09 (1.7, 5.03) 
Diseases of the skin 1 0.21 (0.005, 1.14) 
Endocrine and metabolic diseases 36 7.41 (5.24, 10.11) 
Diabetes mellitus 3 0.62 (0.13, 1.79) 
Disorders of endocrine glands 8 1.65 (0.71, 3.22) 
Metabolic disorders 25 5.14 (3.36, 7.50) 
Miscellaneous 7 1.44 (0.58, 2.94) 
Overall infectious diseases 44 9.05 (6.65, 11.96) 
Sepsis 7 1.44 (0.006, 2.94) 
Infections of the skin and subcutaneous tissue 13 2.67 (1.43, 4.53) 
Infectious arthropathies 4 0.82 (0.22, 2.10) 
Intestinal infectious diseases 1 0.21 (0.00005, 1.14) 
Respiratory infectious diseases 17 3.5 (2.05, 5.54) 
Viral infection 3 0.62 (0.13, 1.79) 
Other infectious diseases 3 0.62 (0.13, 1.79) 
Trauma or injury related condition 3 0.62 (0.13, 1.79) 
Vascular access  95 19.55 (16.11, 23.36) 
Complications 22 4.53 (2.86, 6.77) 
Creation 72 14.81 (11.77, 18.29) 
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Table 5.3. The ratio of the mean number of hospital bed days per patient-year on dialysis for each cause of 
hospital admission in turn, compared all other disease groups combined. 
Cause of hospitalisation 
Unadjusted ratios of 
mean number of bed 
days per patient-year 
at risk 
(95% CIs) p-value 
Adjusted ratios of 
mean number of bed 
days per patient-year 
at risk 
(95% CIs)* p-value 
(N=208 patients) (N=208 patients) 
Anaemia 0.74 (0.39, 1.43) 0.38 0.92 (0.57, 1.49) 0.75 
Diseases of the circulatory system 1.62 (0.97, 2.71) 0.07 1.70 (1.11, 2.61) 0.01 
Diseases not of the circulatory system 1 _ 1 _ 
Hypertensive disease 1.53 (0.73, 3.24) 0.26 1.76 (0.97, 3.21) 0.06 
Ischaemic heart disease 2.05 (0.70, 6.07) 0.19 2.07 (0.90, 4.77) 0.09 
Other forms of heart disease 1.66 (0.78, 3.52) 0.19 1.56 (0.81, 3.02) 0.18 
Cerebrovascular disease 0.79 (0.30, 2.10) 0.64 0.66 (0.30, 1.46) 0.31 
Vascular disease 1.27 (0.69, 2.32) 0.44 1.50 (0.83, 2.70) 0.17 
Diseases of the digestive system 0.98 (0.58, 1.66) 0.94 0.95 (0.59, 1.55) 0.85 
Diseases of the genitourinary system 0.69 (0.51, 0.95) 0.02 0.71 (0.54, 0.94) 0.02 
Diseases of the musculoskeletal system 1.78 (0.53, 5.98) 0.35 2.51 (0.58, 10.93) 0.22 
Diseases of the nervous system 0.65 (0.35, 1.22) 0.18 0.49 (0.27, 0.86) 0.01 
Diseases of the respiratory system 0.70 (0.30, 1.61) 0.4 0.63 (0.29, 1.40) 0.26 
Endocrine and metabolic diseases 0.94 (0.44, 2.01) 0.88 0.87 (0.51, 1.47) 0.6 
Non-endocrine, non-metabolic disease 1 _ 1 _ 
Diabetes mellitus 0.53 (0.27, 1.04) 0.06 0.50 (0.26, 0.98) 0.04 
Disorders of endocrine glands 0.41 (0.24, 0.70) 0.001 0.36 (0.21, 0.63) <0.0001 
Metabolic disorders 1.20 (0.51, 2.85) 0.68 0.11 (0.62, 2.01) 0.72 
Miscellaneous 0.44 (0.14, 1.38) 0.16 0.39 (0.14, 1.06) 0.07 
Overall infectious diseases 1.13 (0.68, 1.87) 0.65 1.06 (0.72, 1.57) 0.76 
Non-infectious diseases 1 _ 1 _ 
Sepsis 0.96 (0.35, 2.62) 0.94 0.95 (0.43, 2.07) 0.9 
Infections of the skin and subcutaneous tissue 1.54 (0.57, 4.18) 0.4 1.12 (0.61, 2.07) 0.7 
Infectious arthropathies 0.91 (0.50, 1.65) 0.75 1.16 (0.50, 2.71) 0.73 
Respiratory infectious diseases 1.10 (0.36, 3.36) 0.87 0.96 (0.47, 1.98) 0.92 
Viral infection 1.05 (0.33, 3.35) 0.94 1.36 (0.58, 3.21) 0.48 
Other infectious diseases 0.93 (0.49, 1.77) 0.83 0.87 (0.46, 1.68) 0.69 
Trauma or injury related condition 0.31 (0.22, 0.44) <0.0001 0.26 (0.14, 0.49) <0.0001 
Vascular access  0.70 (0.48, 1.01) 0.06 0.70 (0.51, 0.97) 0.03 
Non-vascular access causes 1 _ 1 _ 
Complications 1.08 (0.51, 2.31) 0.84 0.91 (0.52, 1.58) 0.74 
Creation 0.61 (0.43, 0.87) 0.007 0.64 (0.45, 0.91) 0.01 
 
CIs=Confidence intervals, *Adjusted for age, sex, and causes of renal disease. 
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Table 5.4. A - Adjusted ratio of the mean number of hospital bed days per patient-year on dialysis by patient 
characteristics at baseline. Data is analysed separately for each reason for hospital admissions in turn 
Predictors Anaemia 
Diseases of the 
circulatory 
system 
Diseases of the 
digestive 
system 
Diseases of the 
genitourinary 
system 
Diseases of the 
musculo-
skeletal system 
Diseases of the 
nervous 
system 
Ratios of mean number of hospital bed days per patient year on dialysis (95% CIs) 
Age  
Per year 1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.03) 
1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.03) 
1.02 (1.01, 
1.03) 
1.02 (1.01, 
1.04) 
Sex 
Female 1 1 1 1 1 1 
Male 0.91 (0.65, 
1.28) 
0.92 (0.67, 
1.27) 
0.91 (0.65, 
1.28) 
0.95 (0.68, 
1.34) 
0.95 (0.68, 
1.34) 
0.90 (0.64, 
1.27) 
Cause of renal disease 
Hypertension 1 1 1 1 1 1 
Glomerulonephri
tis 
1.5 (0.50, 3.84) 1.51 (0.54, 
4.26) 
1.51 (0.59, 
3.84) 
1.51 (0.60, 
3.83) 
1.51 (0.60, 
3.83) 
1.52 (0.60, 
3.81) 
Diabetes 1.36 (0.87, 
2.13) 
1.40 (0.94, 
2.10) 
1.36 (0.87, 
2.13) 
1.40 (0.92, 
2.14) 
1.40 (0.92, 
2.14) 
1.37 (0.87, 
2.15) 
Others 1.44 (0.92, 
2.27) 
1.33 (0.87, 
2.04) 
1.44 (0.92-
2.27) 
1.38 (0.89, 
2.14) 
1.38 (0.89, 
2.14) 
1.44 (0.92, 
2.26) 
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Table 4.4. B - Adjusted ratio of the mean number of hospital bed days per patient-year on dialysis by patient 
characteristics at baseline. Data is analysed separately for each reason for hospital admissions in turn 
Predictors 
Diseases of 
the 
respiratory 
system 
Endocrine and 
metabolic 
diseases 
Vascular 
access 
Overall 
infectious 
diseases 
Miscell-
aneous 
Trauma or 
injury related 
condition 
Ratios of mean number of hospital bed days per patient year on dialysis (95% CIs) 
Age 
Per year 1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.04) 
1.02 (1.01, 
1.04) 
Sex 
Female 1 1 1 1 1 1 
Male 0.91 (0.64, 
1.27) 
0.90 (0.64, 
1.27) 
0.93 (0.66, 
1.30) 
0.91 (0.65, 
1.28) 
0.91 (0.65, 
1.28) 
0.91 (0.65, 
1.28) 
Cause of renal disease 
Hypertension 1 1 1 1 1 1 
Glomerulonephr
itis 
1.57 (0.60, 
4.09) 
1.50 (0.59, 
3.81) 
1.52 (0.63, 
3.66) 
1.51 (0.60, 
3.76) 
1.52 (0.60, 
3.83) 
1.51 (0.59, 
3.84) 
Diabetes 1.38 (0.88, 
2.17) 
1.35 (0.86, 
2.11) 
1.38 (0.89, 
2.13) 
1.36 (0.86, 
2.16) 
1.38 (0.88, 
2.17) 
1.37 (0.88, 
2.15) 
Others 1.45 (0.93, 
2.28) 
1.45 (0.92, 
2.28) 
1.42 (0.91, 
2.22) 
1.44 (0.92, 
2.27) 
1.46 (0.93, 
2.29) 
1.46 (0.93, 
2.30) 
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Table 5.5. Incidence rate ratio of the number of admissions per patient-year on dialysis 
Predictors 
Unadjusted IRR 
(95% CI) 
(N= 318 patients) 
p-value 
*Adjusted IRR 
(95% CI) 
(N= 286 patients) 
p-value 
**Adjusted IRR 
(95% CI) 
(N= 318 patients) 
p-value 
Age 
Per year of age 1.02 (1.01, 1.03) 0.001 1.02 (1.01, 1.03) <0.0001 1.02 (1.01, 1.03) <0.0001 
Sex 
Female 1 _ 1 _ 1 _ 
Male 1.16 (0.84, 1.60) 0.37 1.23 (0.90, 1.67) 0.19 1.17 (0.88, 1.56) 0.29 
Access type at first dialysis 
AVF 1 _ 1 _ _ _ 
AVG 1.46 (0.42, 5.09) 0.55 1.19 (0.37, 3.80) 0.77 _ _ 
Catheter 1.84 (0.97, 3.48) 0.06 1.62 (0.90, 2.90) 0.11 _ _ 
PD 0.42 (0.03, 5.03) 0.49 0.61 (0.06, 6.29) 0.68 _ _ 
Access type during follow-up 
AVF 1 _ _ _ 1 _ 
AVG 1.23 (0.27, 5.55) 0.78 _ _ 0.77 (0.18, 3.27) 0.72 
Catheter 2.93 (1.36, 6.33) 0.006 _ _ 2.55 (1.26, 4.97) 0.009 
Causes of renal disease 
Hypertension 1 _ 1 _ 1 _ 
Glomerulonephritis 2.04 (0.96, 4.36) 0.6 2.20 (1.09, 4.44) 0.03 2.28 (1.14, 4.55) 0.02 
Diabetes 2.50 (1.75, 3.58) <0.0001 2 (1.38, 2.88) <0.0001 1.84 (1.29, 2.63) 0.001 
Other 0.95 (0.61-1.49) 0.84 1.04 (0.66-1.65) 0.85 1.05 (0.68-1.62) 0.81 
 
IRR= incidence rate ratio, AVF= arteriovenous fistula, AVG= arteriovenous graft, PD= peritoneal dialysis 
* adjusted for age, sex, access type at start of dialysis, and cause of renal disease 
** adjusted for age, sex, access type during follow-up, and cause of renal disease 
119 
Discussion 
This study gives an overview of the primary reasons and indications for hospitalisation among 
ESRD patients on haemodialysis in one of the most active MOH hospitals in Makkah City in 
the western region in Saudi Arabia, which may reflect the severity of patients’ co-morbid 
conditions or the quality of renal care practices. This study highlights the most common 
causes of hospitalisation among haemodialysis patients, which were genitourinary diseases 
(35.7-44.6%), cardiovascular diseases (19-26.6%), vascular access (16.1-23.4%), infectious 
diseases (6.6-12%), and endocrine and metabolic diseases (5.2-10.1%). The length of stay in 
hospital usually represents the severity of illness and underlying patient health status. This 
study shows that cardiovascular diseases had the highest impact on an increase in the 
number of hospital bed days per patient-year on dialysis by 70% compared to other reasons 
for hospital admission. 
Cardiovascular disease is uniquely different in patients with ESRD from those in the general 
population with earlier onset in life (236, 239-245). Several studies have suggested that the 
annual rate of hospitalisation and mortality due to cardiovascular disease among patients 
with ESRD is substantially higher than in general population (159, 212, 235). This study found 
that cardiovascular disease was the most common reason for hospitalisation, particularly 
coronary artery disease, which is similar to the general population in Saudi Arabia (246). This 
may be the result of an increase in the prevalence of coronary artery disease risk factors in 
the Saudi population such as smoking (247), obesity, metabolic syndrome, diabetes, and 
hypertension with poor management of chronic diseases or undiagnosed cases (49, 121, 122, 
171, 248). These risk factors are strongly associated with an increased risk of developing 
cardiovascular disease, which may often occur before ESRD (239, 249). Furthermore, this 
study found that an increase in one year of a patient’s age, which is an un-modifiable risk 
factor, had a significant effect in increasing the length of stay in hospital and the rate of 
admissions by 2% per patient-year on haemodialysis. Diabetes as a cause of renal disease, 
and using a catheter as access point for haemodialysis also had a significant effect on the 
increasing rate of admissions. 
In this study, only 7% of haemodialysis patients commenced dialysis with AVF, while the 
NKF/KDOQI and the Renal Association guidelines for vascular access have recommended that 
65% of all incident haemodialysis patients should initiate dialysis with AVF (183, 250). 
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Although the vast majority of the study population commenced haemodialysis with a catheter 
as a result of late referral to nephrology care, most of them had converted throughout 
dialysis time to AVF which is considered as a modifiable risk factor for reducing vascular 
access complications, especially catheter related infection, and lowering the risk of 
hospitalisation, as this study demonstrated that patients who had used a catheter throughout 
the follow-up period showed a 2.5-fold increase in the rate of hospital admissions compared 
to those who had used AVF. Therefore, the high prevalence of hospital admissions due to 
vascular access throughout haemodialysis was attributed to creating AVF as a permanent 
vascular access rather than vascular access complications which also contributed to an 
increase in hospital utilisation and the cost of haemodialysis care. 
The findings of this study demonstrate that the goals of vascular access placement for the 
NKF/KDOQI and The Renal Association guidelines (183, 250) have been achieved in AKC, 
whereas the prevalent functional AVF placement rate was around 95% of patients in AKC in 
2011, which is higher than the recommended goal of over 65% in NKF KDOQI and 85% in the 
Renal Association. However, according to the Saudi Centre for Organ Transplantation data 
report in 2011, the prevalent functional AVF placement rate in all centres in Saudi Arabia was 
71% of patients (60), which is lower than the rate in AKC. This indicates the differences in 
haemodialysis practices and outcomes between healthcare centres. This in turn implies the 
diversity and cultural competence training in healthcare institutions, or the inequality in 
allocating healthcare resources between healthcare centres in Saudi Arabia, particularly 
healthcare providers specialist in nephrology care (27). 
Limitations 
The potential limitations of this study were that the study was conducted retrospectively for 
prevalent patients in 2011 due to three main reasons: time limitations for collecting data, a 
lack of national health information systems in Saudi Arabia, and because some patients were 
not receiving healthcare in one hospital during the follow-up period of the study. Therefore, it 
was not possible to examine the trend in the annual rate of hospitalisation for all causes of 
hospital admission and look at whether there was any significant change in the rate, which 
might indicate a change in the quality of delivering healthcare services in recent decades. 
Also, a large amount of critical data for many patients were missing, such as clinical and 
laboratory measurements at start of dialysis, and the time at which all co-morbid conditions 
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were diagnosed. Besides, around one-third of the study sample did not have any reported 
hospitalisation in Al Noor Specialist Hospital. Those patients may have come to the AKC for 
dialysis sessions as outpatients and may have been hospitalised in another hospital such as a 
private hospital for inpatient care, or their health conditions may have been good and may 
not have required hospitalisation. Also, some patients in the study sample who reported 
admissions might also had undergone admissions in other hospitals. These issues could affect 
the imprecision of the results. Furthermore, in hospital admissions data records, some 
patients’ diagnoses and procedures may have been incorrectly reported or coded. In addition, 
the IRR of the admission or length of stay in hospital might not reflect patients’ health 
conditions due to inappropriate hospitalisation in the governmental hospitals in Saudi Arabia. 
Notably, a survey based on physicians’ perspectives highlighted that inappropriate 
hospitalisation occurred mostly because there was nobody able to look after the patients 
outside the hospital (251). This is particularly true for elderly patients who require more care 
than younger patients, as demonstrated in this study by the strong association of the rate of 
length of stay in hospital and the rate of admissions with increasing patient age. 
Inappropriate hospitalisation might not be the reason for the increase in the rate of length of 
stay in hospital or admissions among haemodialysis patients in this study population. An 
increase in the rate of length of stay in hospital in this study might really reflect the severity 
of patients’ co-morbid conditions disease especially among elderly patients as a result of 
rapid progression of chronic diseases and their complications. 
Strengths 
This study reveals that the most frequent reasons for hospital admission among 
haemodialysis patients were cardiovascular disease particularly hypertension and coronary 
artery disease, vascular access due to creating AVF after starting dialysis, infectious diseases 
particularly respiratory infectious disease, and endocrine and metabolic disorders. Increased 
age, diabetes as a cause of renal disease, and using a catheter as access point for 
haemodialysis have a significant effect in increase the rate for hospital admissions per 
patient-year on haemodialysis. These indications for hospital admissions provide evidence for 
public health administrators and healthcare providers in Saudi Arabia to develop 
multidisciplinary strategies for improving pre-ESRD nephrology care practice, and the quality 
of healthcare management for multiple chronic diseases and their complications, patients’ 
122 
health behaviours and awareness about their illness. These strategies would be valuable in 
the future to improve healthcare outcomes and reduce hospital utilization and the cost of 
haemodialysis care. Furthermore, this study suggests that health information systems must 
be developed in Saudi Arabia to allow further research to be conducted to review regularly 
the quality of haemodialysis cares and outcomes in all MOH and non-MOH centres. More 
indications for hospitalisation and consequences of practices related to hospitalisation for 
haemodialysis patients should be studied to provide a comprehensive evidence-based health 
policy for haemodialysis patients in Saudi Arabia. 
Conclusion 
This study describes all of the relevant literature related to the aetiology of renal disease in 
Saudi Arabia. The findings of this study are that diabetes and hypertension are the most 
prevalent causes of ESRD, and that increased age and diabetes as a cause of ESRD has a 
significant contribution in the increased rate of hospital admissions among haemodialysis 
patients. Thus cardiovascular disease was the most common reason for hospital admission, 
and had a significant impact to increase the length of stay in hospital with increasing age. 
Furthermore, pre ESRD nephrology care practice should be improved to reduce or eliminate 
initiating dialysis with catheter which associate with increase the rate of hospital admission 
among haemodialysis patients. Health information systems must be developed in Saudi 
Arabia to allow further researches to be conducted to investigate other indications for 
hospitalisation such as clinical and laboratory measurements, and healthcare providers 
specialist services; and consequences of practices related to hospitalisation for haemodialysis 
patients to provide a comprehensive evidence-based health policy for haemodialysis patients 
in Saudi Arabia. 
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CHAPTER 6 
Conclusions and recommendations 
With limited healthcare resources, the pattern of disease has changed in Saudi Arabia in 
recent decades from communicable to non-communicable diseases (4) as a result of the rapid 
economic growth that is contributing to increased health risk behaviours in Saudi Arabia, 
including lack of physical activity, poor nutrition, and smoking (49, 247, 252-255). These are 
responsible for much of the illness, suffering, and early deaths related to chronic diseases in 
Saudi Arabia (256). Many reports in the literature have shown that the prevalence of obesity 
(26, 49), diabetes mellitus (122, 125), and cardiovascular disease (121, 257) are high in the 
Saudi population. All these are risk factors for developing chronic kidney disease (CKD) 
besides a family history of CKD and increased age. Chronic kidney disease is becoming a 
worldwide public health problem as it is linked with an increase in the incidence and 
prevalence rate of patients with renal failure who require renal replacement therapy with 
high healthcare costs and poor outcomes. Moreover, CKD in its earlier stages is associated 
with a higher prevalence of many adverse outcomes such as renal failure, cardiovascular 
disease, and premature death (258). Therefore, more attention to the prevention and 
management of CKD is required in Saudi Arabia. 
Poor management of diabetes and hypertension increases the risk of progression of CKD to 
end-stage renal failure. Also, infections, and conflicts in prescribing medications (259, 260) or 
toxins injurious to the kidney can contribute to progression of CKD to end-stage renal failure 
particularly in the elderly people in Saudi Arabia. The incidence rate of end-stage renal 
disease (ESRD) has increased substantially in Saudi Arabia with a large proportion of incidence 
and prevalence of ESRD found among middle-aged patients, while the proportion of males is 
slightly higher than females but there was no significant different between them. The 
predominant causes of ESRD in Saudi Arabia are diabetes and hypertension. The prevalence 
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of diabetic nephropathy as a cause of ESRD has increased significantly in all regions of Saudi 
Arabia in the past two decades, while the trend of hypertensive nephropathy has not 
changed, and with the changing patterns of disease the prevalence of glomerulonephritis as a 
cause of ESRD has decreased remarkably. This means that diabetes has a significant 
contribution in increasing the risk of ESRD in Saudi Arabia. 
Furthermore, the majority of patients with CKD who progressed to ESRD were referred from 
an emergency department for urgent dialysis in two of the most active Ministry of Health 
(MOH) hospitals in the western region of Saudi Arabia. This implies that patients, who are 
diabetic or hypertensive during middle-age, and at high risk for progression of CKD were not 
detected in the general population, or they were diagnosed but were not followed up 
consistently, or they were not educated efficiently about their illness and its potential 
complications. This reveals the current status of chronic diseases management, including CKD 
in Saudi Arabia, and emphasises the importance of developing multidisciplinary preventive 
strategies to prevent or delay the progression of renal disease, and reduce the incidence rate 
of ESRD and its complications, and related healthcare cost. The National Kidney Foundation – 
Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines states that adverse 
outcomes of CKD, such as loss of kidney function, kidney failure, and cardiovascular disease, 
can be prevented or delayed by detecting and treating CKD at earlier stages (185). 
This strategy includes consistently first detecting and screening people at high risk of CKD 
who are often diabetic or hypertensive in the Saudi population. The NHS Health Check 
Programme for adults in England may be a model that could be considered in Saudi Arabia to 
help achieve this objective (261). Second, improving the rate of early referral of patients with 
CKD to nephrology care; this will be achieved by increasing the awareness of other healthcare 
professionals, including primary care physicians, cardiologists, diabetologists, and internists 
about the importance of early diagnosis and effective treatment measures of CKD. Also, 
encouraging communication between healthcare practitioners, and closer collaboration 
between primary and secondary healthcare professionals in all healthcare sectors in Saudi 
Arabia to provide optimal renal care, which includes creating guidelines for other healthcare 
professionals that clarify the criteria of when the patient with CKD should be referred to 
nephrology care, and educate patients about their illness and train them for self-
management. Improving the rate of early referral to nephrology care for patients with CKD 
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also give patients who are expected to progress to ESRD the chance to consider and decide 
between renal replacement therapy (RRT) options. This will help to improve pre-emptive 
renal transplantation, and allow time to create arteriovenous fistula as a permanent vascular 
access point for dialysis, which is considered a modifiable risk factor for vascular access 
complications; thus the hospital utilisation and healthcare cost will be reduced. 
Investigating morbidity conditions among patients with ESRD in Saudi Arabia revealed that 
the highest prevalence morbidity conditions were hypertension and Hepatitis C Virus (HCV) 
infection. Although the prevalence of HCV has apparently declined in recent decades among 
patients with ESRD in Saudi Arabia, there are many factors contributing to the high 
prevalence of HCV particularly among haemodialysis patients. These factors include the 
effects of nurse understaffing, which means that the staff were not highly trained overall. 
Other factors may increase the risk of HCV, such as the length of dialysis, or the number of 
blood transfusions that might have involved incomplete or absent anti-HCV screening of 
donated blood. The relations between all these factors and the high prevalence of HCV, which 
is associated with a high rate of chronic liver disease and cirrhosis, among haemodialysis 
patients should be investigated in a prospective longitudinal study to provide a 
comprehensive evidence-based health policy. 
Cardiovascular disease was the leading cause of hospitalisation and mortality among patients 
with ESRD in Saudi Arabia. Investigating the indications for hospitalisation, which usually 
reflect either the quality of healthcare services, or the severity of patients’ co-morbid 
conditions, among haemodialysis patients in one of the most active MOH hospitals in Makkah 
City in the western regions of Saudi Arabia has revealed that diabetes and hypertension are 
the most common causes of ESRD, and that increased age and diabetes as a cause of ESRD 
has a significant contribution in the increased rate of hospital admissions among 
haemodialysis patients. Thus cardiovascular disease was the most common reason for 
hospital admission, and had a significant impact to increase the length of stay in hospital with 
increasing age. However, CKD is an important risk factor for cardiovascular disease even 
before progressing to ESRD and onset RRT, while other risk factors for cardiovascular disease 
that require careful attention in people with CKD include smoking tobacco and water pipes, 
uncontrolled high blood pressure, elevated blood sugar, excessive weight, and elevated 
cholesterol (262). Further studies are needed to investigate more indications for 
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hospitalisation among patients with ESRD in Saudi Arabia to assess the effect of pre-ESRD 
care practice, clinical and laboratory measurement at onset of ESRD, and the specialised 
healthcare providers; to provide evidence based-health policy to improve the quality of 
healthcare management for those individuals at high risk of CKD in Saudi population, and 
reduce the cost of healthcare. 
The national health information system must be developed in Saudi Arabia to provide 
comprehensive data on the health of the populations and its use of health services. Also, 
healthcare practitioners should be trained on how to report and code the diagnosis and 
healthcare procedures correctly. This will play the main role in developing the preventive 
strategy of CKD and its risk factors, and improve the communication between healthcare 
providers to implement the best healthcare practice, which would help in reducing medical 
errors and duplications of healthcare services. Also, it will help in conducting further studies 
for assessing the overall quality of renal care regularly to provide an updated evidence-based 
health policy. The further studies should be concern with: 
● Assessing and describing the epidemiology of CKD and ESRD to improve the quality of 
healthcare management. For instance, tracking the trend of the incidence rate of ESRD 
among diabetic or hypertensive patients. Also, a longitudinal study is required to 
investigate the reason for the high prevalence of HCV among haemodialysis patients. 
● Evaluating pre-ESRD care practice and its outcomes in order to implement the best 
intervention that will help to improve pre-ESRD care practice outcomes in Saudi Arabia. 
Particularly, the best time of referring patients with CKD to nephrology care should be 
investigated. 
● Investigating other indications for hospitalisation such as clinical and laboratory 
measurements, healthcare providers specialist services, and consequences of healthcare 
practices that related to hospitalisation among haemodialysis patients. 
 
In summary, this thesis presents an evidence of the increasing burden of ESRD in Saudi 
Arabia. It stressed the needs and the importance of multidisciplinary preventive strategies for 
leading causes of ESRD, which are diabetes and hypertension. Also, it provides an evidence 
for the need of improving pre-ESRD nephrology care practice and the collaboration between 
healthcare providers. Furthermore, it highlights the need for a comprehensive national health 
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information system to allow regular screening for those people at high risk and to detect CKD 
in the early stages and to describe the epidemiological pattern of ESRD in Saudi Arabia. This 
would allow the identification of priority areas for further research to assess the quality of 
healthcare management and provide an updated evidence-based health policy that will help 
healthcare providers to choose the best intervention that will help to improve healthcare 
practice outcomes for patients with CKD and allocate healthcare resources appropriately. 
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Appendices 
Appendix A - Search strategy 
1 ((end stage or terminal or chronic) adj3 (renal* or kidney*)).mp. [mp=ab, sh, hw, ti, 
tn, ot, dm, mf, nm, ui, an] 
2 ((Saudi or emirates or Kuwait or Oman or Bahrain or Qatar) adj5 (middle east* or 
Arab*)).mp. [mp=ab, sh, hw, ti, tn, ot, dm, mf, nm, ui, an] 
3 1 and 2   
146 
Appendix B - Data extraction form 
Page 1 
 
Data Extraction Form for a systematic review of the epidemiology of end-stage renal disease 
in the countries of the Gulf Cooperation Council  
Reviewer initial:                                                                     S tudy ID:  (Author: Year) 
 
Description of the study 
Study design 
 
  Cohort                    Case-control             
  Cross-sectional     Ecological Study 
The objective of the study 
 
  Incidence                                                                                                     
  Prevalence                                                                                                   
  Mortality rate                                                                                               
  Causes of Mortality         
  Primary causes co-morbidities 
  Co-morbid conditions 
Validation of ESRD   Biochemical or medical record          Self-report 
Renal replacement modalities 
 
  Renal Transplantation [      %]               
  Dialysis (Haemodialysis [      %] – Peritoneal dialysis [      %]) 
Study setting  Country: 
How many centres: 
Population size: 
Age: 
Sex:   Male [      %]            Female [      %]  
Duration of dialysis:              
 
 
Participants 
Inclusion criteria 
 
 
 
Exclusion criteria 
 
 
 
 
 
Participants studied 
 
Disease No disease   Notes                       
Number enrolled into study 
 
   
Number lost to follow up  
 
   
Final number of participants 
evaluated  
   
 
Assessing the methodological quality of the study 
Newcastle – 
Ottawa Scale 
Case-control studies & 
Cross-sectional studies 
 Cohort studies  
1. Selection   Case definition                                    
  Representativeness of cases 
  Selection of control 
  Definition of controls 
   Representativeness of exposed 
cohort 
  Selection of non exposed cohort 
  Ascertainment of exposure 
  Outcome occurred  
 
2. Comparability   Matching / adjustment for age 
  Matching / adjustment for other 
factors 
Factors=…………………………… 
   Matching / adjustment for age 
  Matching / adjustment for other 
factors 
Factors=…………………………………
…. 
 
3. 
Ascertainment  
  Ascertainment of exposure  
  Same method of ascertainment for 
cases and controls 
  Non response rate 
   Ascertainment of outcome 
  Was follow up long enough for 
outcomes to occur 
  Adequacy of follow up of cohort 
 
Score: 
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Page2 
 
 
Data Extraction Form for a systematic review of the epidemiology of end-stage renal disease 
in the countries of the Gulf Cooperation Council  
Reviewer initial:                                                                     S tudy ID:  (Author: Year) 
 
 
Primary outcome measures 
 
1- End-stage Renal Disease  
□ Prevalence rate  
□ Incidence rate    
□ Mortality rate   
 
2- □ Primary causes  
 
3- □ Co-morbid conditions 
 
4- □ Mortality causes   
 
 
 
Results  
Primary Outcomes Group,              N= 
 
 
Group,            N= Group,         N=        
 
 
 
 
  
  
 
  
 
 
 
 
  
    
 
 
   
 
 
   
 
 
   
    
    
    
 
Additional notes 
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Appendix C - Causes of hospitalization 
Non-infectious diseases 
Anaemia 
● D50 Iron deficiency anemia 
● D59 Acquired hemolytic anemia 
● D63 Anemia in other chronic diseases classified elsewhere 
● D64 Other anemias 
● D69 Purpura and other hemorrhagic conditions 
Diseases of the musculoskeletal system 
● M84 Disorder of continuity of bone 
● M90 Osteopathies in diseases classified elsewhere 
● M96 Intraoperative and postprocedural complications and disorders of musculoskeletal system, not 
elsewhere classified 
Diseases of the digestive system 
● K21 Gastro-esophageal reflux disease 
● K25 Gastric ulcer 
● K29 Gastritis and duodenitis 
● K35 Acute appendicitis 
● K40 Inguinal hernia 
● K42 Umbilical hernia 
● K57 Diverticular disease of intestine 
● K59 Other functional intestinal disorders 
● K60 Fissure and fistula of anal and rectal regions 
● K61 Abscess of anal and rectal regions 
● K62 Other diseases of anus and rectum,subcoding 
● K74 Fibrosis and cirrhosis of liver 
● K76 Other diseases of liver 
● K80 Cholelithiasis 
● K81 Cholecystitis 
● K85 Acute pancreatitis 
● K92 Other diseases of digestive system 
● R10 Abdominal and pelvic pain 
● R18 Ascites 
● R19 Other symptoms and signs involving the digestive system and abdomen 
● R19 Other symptoms and signs involving the digestive system and abdomen 
Disease of the nerve system 
● G40 Epilepsy and recurrent seizures 
● G56 Mononeuropathies ofupper limb 
● G81 Hemiplegia and hemiparesis 
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● R52 Pain, unspecified 
● R56 Convulsions, not elsewhere classified 
Diseases of the respiratory system 
● J45 Asthma 
● J81 Pulmonary oedema 
● J86 Pyothorax 
● J90 Pleural effusion, not elsewhere classified 
● J93 Pneumothorax and air leak 
● R04 Hemorrhage from respiratory passages 
● R09 Other symptoms and signs involving the circulatory and respiratory system 
Diseases of the genitourinary system 
● N05 Unspecified nephritic syndrome 
● N13 Obstructive and reflux uropathy 
● N18 Chronic kidney disease 
● N20 Calculus of kidney and ureter 
● N21 Calculus of lower urinary tract 
● N23 Unspecified renal colic 
● N25 Disorders resulting from impaired renal tubular function 
● N39 Other disorders of urinary system 
● N40 Enlarged prostate 
● N93 Other abnormal uterine and vaginal bleeding 
● Q61 Cystic kidney disease 
● Q64 Other congenital malformations of urinary system 
● Q87 Other specified congenital malformation syndromes affecting multiple systems 
● R33 Retention of urine 
● R87 Abnormal findings in specimens from female genital organs 
● Z49 Encounter for care involving renal dialysis 
● Z94 Transplanted organ and tissue status 
Diseases of the circulatory system 
● I10 Essential (primary) hypertension 
● I11 Hypertensive heart disease 
● I12 Hypertensive chronic kidney disease 
● I21 ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction 
● I24 Other acute ischemic heart diseases 
● I25 Chronic ischemic heart disease 
● I30 Acute pericarditis 
● I31 Other diseases of pericardium 
● I42 Cardiomyopathy 
● I44 Atrioventricular and left bundle-branch block 
● I47 Paroxysmal tachycardia 
● I48 Atrial fibrillation and flutter 
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● I50 Heart failure 
● I60 Nontraumatic subarachnoid hemorrhage 
● I63 Cerebral infarction 
● I67 Other cerebrovascular diseases 
● I70 Atherosclerosis 
● I74 Arterial embolism and thrombosis 
● I82 Other venous embolism and thrombosis 
● I95 Hypotension 
● I96 Gangrene, not elsewhere classified 
● I97 Intraoperative and postprocedural complications and disorders of circulatory system, not 
elsewhereclassified 
● O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium 
● R00 Abnormalities of heart beat 
Disease of the skin 
● L98 Other disorders of skin and subcutaneous tissue, not elsewhere classified 
Endocrine and metabolic diseases 
● E08 Diabetes mellitus due to underlying condition 
● E16 Other disorders of pancreatic internal secretion 
● E21 Hyperparathyroidism and other disorders of parathyroid gland 
● E83 Disorders of mineral metabolism 
● E87 Other disorders of fluid, electrolyte and acid-base balance 
Miscellaneous 
● O14 Pre-eclampsia 
● Z93 Artificial opening status 
● Z98 Other postprocedural states 
Trauma or injury related condition 
● S31 Open wound of abdomen, lower back, pelvis and external genitals 
● T14 Injury of unspecified body region 
● T86 Complications of transplanted organs and tissue 
● T81 Complications of procedures, not elsewhere classified 
Vascular access [creation, problem] 
● T80 Complications following infusion, transfusion and therapeutic injection 
● T81 Complications of procedures, not elsewhere classified 
● T82 Complications of cardiac and vascular prosthetic devices, implants and grafts 
● Z49 Encounter for care involving renal dialysis 
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Infectious disease 
Sepsis 
● A41 Other sepsis 
Infections of the skin and subcutaneous tissue 
● L02 Cutaneous abscess, furuncle and carbuncle 
● L03 Cellulitis and acute lymphangitis 
● L04 Acute lymphadenitis 
Infectious arthropathies 
● M00 Pyogenic arthritis 
Intestinal infectious diseases 
● A09 Infectious gastroenteritis and colitis, unspecified 
Respiratory infectious diseases 
● A15 Respiratory tuberculosis 
● A19 Miliary tuberculosis 
● J02 Acute pharyngitis 
● J18 Pneumonia, unspecified organism 
● J20 Acute bronchitis 
● J69 Pneumonitis due to solids and liquids 
Viral infection 
● B17 Other acute viral hepatitis 
● B34 Viral infection of unspecified site 
● Other infectious diseases 
● H60 Otitis externa 
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